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Sommario 
Mutazioni somatiche nel gene TP53 si verificano in più del 50% di tutti i tumori umani, 
tra questi, il carcinoma ovarico sieroso di alto grado (HGSOC) e il carcinoma mam-
mario basale (BC) sono tra i tumori più frequentemente mutati. Le mutazioni di TP53 
sono prevalentemente di tipo missenso, cioè codificano per forme mutate della pro-
teina p53, causando sia una perdita della funzione wild-type di p53 (wt_p53) che un 
guadagno di caratteristiche pro-tumorigeniche al mutante p53 (mut_p53), la cosiddetta 
gain of function (GOF). Diversi studi hanno dimostrato che la GOF di mut_p53 pro-
muove l'invasività e la metastasi del tumore. Tuttavia, i meccanismi molecolari sotto-
stanti non sono stati completamente caratterizzati. Gli RNA non codificanti, in parti-
colare i lncRNA (long non-coding RNA), sono attori centrali della regolazione genica, 
inclusa la via di wt_p53, ma fino ad oggi non ci sono studi che indaghino il ruolo degli 
lncRNA nel fenotipo pro-invasivo di mut_p53. Pertanto, l’obiettivo di questa Tesi di 
dottorato è indagare, nei modelli cellulari HGSOC e BC, se i lncRNA abbiano un ruolo 
nellla GOF di mut_p53. 
A questo scopo, abbiamo valutato i cambiamenti fenotipici utilizzando saggi di invasi-
vità in vitro (mesothelial clearance e 3D colony assay) nelle linee cellulari HGSOC e BC silen-
ziate per TP53. Per delineare l'espressione dei lncRNA nelle cellule silenziate per TP53, 
abbiamo utilizzato un'analisi di sequenziamento dell'RNA di lunghi RNA nucleari. 
Successivamente, abbiamo convalidato i risultati dell’analisi di deep-sequencing in modelli 
cellulari mut_p53 e wt_p53. 
Abbiamo osservato che mut_p53 migliora la capacità delle cellule di HGSOC di inva-
dere il peritoneo e delle cellule di BC basale di invadere la matrice extracellulare. Dall'a-
nalisi dei dati di deep-sequencing delle cellule silenziate per TP53, abbiamo individuato 
806 e 1820 lncRNA differenzialmente espressi nelle linee cellulari BC e HGSOC, ri-
spettivamente. Usando la tecnica qRT-PCR, abbiamo studiato i 10 geni più differen-
zialmente espressi sia nelle linee cellulari mut_p53 che wt_p53. 
Per riassumere, abbiamo osservato che mut_p53 ha un ruolo nel fenotipo metastatico 
sia nel HGSOC che nel BC e abbiamo identificato alcuni lncRNA (ad esempio 
LINC00704) che potrebbero essere responsabili di questo effetto. Tra i nostri obiettivi 
futuri c’è quello di attivare o reprimere l'espressione di questi geni candidati e valutarne 
l'impatto sulla biologia delle cellule tumorali.  
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Abstract 
Somatic mutations in TP53 gene occur in more than 50% of all human cancers, being 
of high grade serous ovarian carcinoma (HGSOC) and basal breast cancer (BC) among 
the most frequently mutated cancers. TP53 mutations are predominantly missense, 
thus encoding for mutated forms of p53 protein that cause both a loss of wild-type 
p53 (wt_p53) function and a gain of pro-tumorigenic features to mutant p53 
(mut_p53), so called gain of function (GOF). Several studies demonstrated that 
mut_p53 GOF promotes tumor invasiveness and metastasis. However, the molecular 
mechanisms underneath are not fully characterized. Non-coding RNAs, particularly 
lncRNAs (long non-coding RNAs), are central players of gene regulation including 
wt_p53 pathway, but up today there are not reports that investigate the role of 
lncRNAs in the pro-invasive phenotype of mut_p53. Therefore, to better understand 
the mechanism of mut_p53 oncogenic functions, in this PhD thesis, we aim to inves-
tigate whether lncRNAs participate to mut_p53 gain of function, precisely in HGSOC 
and BC cell models. 
To do this, we evaluated changes in in vitro invasiveness assays (mesothelial clearance 
and 3D colony assay) in TP53_silenced HGSOC and BC cell lines. To profile the ex-
pression of lncRNAs in TP53_silenced cells, we used a RNA deep-sequencing analysis 
of nuclear long RNAs. Next, we validated deep-sequencing results in mut_p53 and 
wt_p53 cell models. 
We observed that mut_p53 enhances the ability of HGSOC to invade the peritoneum 
and of basal BC cells to invade extracellular matrix. From NGS data analysis of 
TP53_silenced cells, we discovered 806 and 1820 lncRNAs differentially expressed in 
BC and HGSOC cell lines, respectively. Using qRT-PCR, we investigated the 10 gene 
most differentially expressed both in mut_p53 and wt_p53 cell lines. 
To sum up, we report a role of mut_p53 both in HGSOC and BC metastatic pheno-
type, and we identify some lncRNAs (e.g. LINC00704) which could be accountable of 
this effect. Our future plan is to activate or repress the expression of these candidate 
genes and evaluate the impact on tumor cell biology. 
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1. Introduction 
1.1. TP53 
TP53 gene, the so-called “guardian of the genome” 1, encodes for a tumor suppressor 
transcription factor that is activated in response to stress stimuli and governs an anti-
proliferative and pro-apoptotic transcriptional program 2,3. When TP53 was discovered 
in 1979 4,5, it was described as an oncogene, based on the evidences that p53 was fre-
quently overexpressed in cancers and, when ectopically expressed in primary cells, in-
duced cellular immortalization and transformation. It was later discovered that the 
TP53 gene first cloned was the mutant form, which contained a missense mutation; 
whereas, the wild type form of TP53 behaved like a tumor suppressor gene showing 
opposite effects compared to the mutant one 6. 
 
1.1.1. The structure 
p53 is a 393 amino acids nuclear phosphoprotein with a complex structure that con-
sists of five modular domains (Figure 1) 7,8: 
- two N-terminal transactivation domains (TAD) (amino acids 1-62), 
- a conserved proline-rich region (PRR) (amino acids 63-94), 
- a central DNA-binding domain (DBD) (amino acids 94-292), 
- an oligomerization domain (OD) (amino acids 325-356), which is included in 
- a C-terminal domain (CTD) (amino acids 311-393). 
 
The TADs are fundamental for p53 function because they interact with the compo-
nents of the transcription machinery, (i.e. TATA-binding protein - TBP and the TBP-
associated factors - TAFs) 9–13, and with the acetyltransferases (i.e. p300 and the CREB-
binding protein - CBP) that eventually acetylate the CTD of p53 and regulate its func-
tion 14–16. However, TADs bind also negative regulators (e.g. Mdm2 and Mdmx) pro-
teins that induce p53 degradation through the ubiquitin-dependent proteasome path-
way 17–19. 
 
The PRR consists of five PXXP repeats (P is proline and X any amino acid), its func-
tion is still not completely understood, but it seems to have a negative regulatory role 
on p53 DNA binding activity 20. 
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Figure 1 : p53 structure. p53 contains an unfolded amino-terminal transactivation domain (TAD) subdivided into 
two subdomains (TAD1 and TAD2), followed by a proline-rich region (PRR). The central part is the structured 
DNA-binding (DBD) and tetramerization domains (OD). Likewise the TAD, there is a disordered regulatory do-
main at the extreme carboxyl terminus (CTD). Based on the TP53 Mutation Database of IARC 21, the vertical bars 
indicate the relative missense-mutation frequency in human cancer for each residue, suggesting that most of the cancer mu-
tations are in the DBD. The picture below represents the structure of the DBD, in which is evidenced sites of cancer 
hotspot mutations and essential DNA contacts. Adapted from 7.  
 
The DBD is the core of p53 protein, because it contains the DNA binding activity. It 
has an immunoglobulin-like b-sandwich scaffold and other structural elements (i.e. a 
loop-sheet-helix motif and two large loops stabilized by a zinc ion) that form the 
DNA-binding surface 22–24. Removal of the zinc ion destabilizes the protein and in-
duces the loss of sequence-specific DNA binding activity 25,26. The DBD binds specif-
ically to double-stranded target DNA (DNA response element). The DNA response 
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elements (REs) are bound by four DBD in a 4:1 complex 27, and binding affinity de-
pends on RE sequence: typically, p53 binds with high-affinity to REs of genes involved 
in cell cycle arrest and with low-affinity to REs of genes involved in apoptosis 28,29. The 
p53 OD allows the homo-tetramerization (dimers of dimers) that is necessary to bind 
REs and eventually to activate the transcription of p53 targets 30,31. 
 
The CTD has a regulatory role: it contains a leucine-rich regulatory domain that main-
tains p53 in an inactive form until phosphorylation or acetylation in this domain acti-
vates the protein 32–34. Moreover, it encodes for a nuclear export signal (NES) and a 
nuclear localization signal (NLS), which binds to a receptor and allow the selective 
passage of p53 through the nuclear pores. 
Both N-terminal and C-terminal of p53 have a natively unfolded structure 35, which is 
a typical feature of proteins involved in protein-protein interaction networks 36 because 
it facilitates binding promiscuity and allows to interact with a large number of different 
targets proteins 37. By contrast, the central DBD and the tetramerization domain have 
a well-defined conformation. 
 
In order to activate the downstream cascade, p53 tetramers shift from a latent to an 
active form, and to do so they are post-translationally modified through several mech-
anisms 38–40 (e.g., phosphorylation, glycosylation, acetylation, protein-protein interac-
tions, binding ssDNA, alternative splicing, C-terminal truncation, and N-terminal trun-
cation), which all disrupt the binding between CTD and DBD and eventually make 
the p53 core domain available to bind DNA REs 14. 
 
1.1.2. Wild-type p53 
p53 is a transcription factor, it is the linchpin of a plethora of signaling pathways that 
regulate proliferation, induce cell cycle arrest and apoptosis in response to stress stim-
uli (genotoxic damage, oncogene activation, loss of normal cell contacts, hypoxia, nu-
trient deprivation and telomere erosion) and ultimately maintain the integrity of the 
human genome 41. 
In normal cells, p53 is usually expressed at a very low level cause of Mdm2 binding 
that ubiquitinates the protein and induces p53 degradation 42–44. Stress stimuli rapidly 
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increase p53 protein expression levels, without any effects on TP53 transcription lev-
els. The increase of p53 protein expression levels can occur both by enhancement of 
p53 mRNA translation and the stabilization of p53 protein. The latter is due to various 
post-translational modifications that alter the interaction between p53 and its negative 
regulator Mdm2, which is also one of p53 transcriptional targets, thus creating a neg-
ative feedback loop 45. 
 
p53 acts as tumor suppressor in different ways (Figure 2): 
- Promoting the cell cycle arrest in G1/S phase through the transcription of the 
cyclin-dependent kinase inhibitors (CDKN1A and CDKN2A that encodes for 
p21 and p16, respectively). p21 expression is susceptible to even low levels of 
p53 protein, and this allows cells to safely survive until the damage has been 
resolved or stress removed 46. 
- Promoting the cell cycle arrest in G2/M phase through the transcription of 
GADD45 genes. Gadd45 interacts with different proteins involved in cell cycle 
regulation (i.e., Cdc2 and PCNA) 46. 
 
If DNA damage repair is not possible, p53 activates apoptotic pathways to avoid the 
proliferation of damaged cells 47. To do this, p53: 
- promotes apoptosis through the activation of PUMA, a member of pro-apop-
totic Bcl2- family, that induces the mitochondrial-dependent apoptosis 48. 
- Promotes senescence through the expression of plasminogen activator inhibi-
tor 1 (PAI-1) 49,50 and p21 51. 
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Figure 2: p53 tumor suppressor functions. p53 controls cell survival, proliferation and cell death regulating the 
expression of different target genes (some of them are reported in blue in this image). Adapted from 41. 
 
Moreover, p53 protects cells against DNA damage and genome instability using dif-
ferent mechanisms: 
- decreasing the levels of intracellular reactive oxygen species 52,53. 
- Regulating the metabolism. Indeed, one of the cancer cell features is the ability 
to survive under adverse conditions (i.e. starvation) 54. In this situation p53 is 
activated by AMP-activated prion kinase (AMPK) 55 and negatively regulates 
the kinase mTOR (mammalian target of rapamycin) which is important in the 
control of protein synthesis 56,57. 
- Regulating autophagy, a membrane trafficking-mediated “self-eating” mecha-
nism that results in lysosomal digestion of cellular components. To do this, 
p53 induces lysosomal proteins such as DRAM (damage-regulated autophagy 
modulator) 58 or negative regulates mTOR signaling 59. 
- Modulating glucose uptake 60, in particular, dampening glycolysis 61,62 and im-
proved mitochondrial respiration 63, curbing the acquisition of enhanced aer-
obic glycolysis that is one characteristic metabolic change associated with on-
cogenesis. 
- Promoting antiangiogenic activities that could limit tumor progression 64. 
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Overall, p53 works as a genome guardian because it avoids the accumulation of cells 
with oncogenic mutations within the host. 
 
1.1.3. Mutant p53 in cancer 
Fifty per cent of all human cancers carry a TP53 mutation that makes TP53 the most 
frequent mutated gene and underlies the importance of p53 in tumor biology 65–67. 
Carriers of TP53 germinal mutations develop the Li-Fraumeni syndrome, which is 
characterized by the development of malignant tumors by early adulthood (typically 
breast cancer, sarcomas, brain tumors and adrenocortical carcinomas) 68–71. Moreover, 
TP53 DNA sequence is highly polymorphic both in coding and noncoding regions, 
and some of these polymorphisms have been shown to increase cancer susceptibility 
and to modify cancer phenotypes 72. 
TP53 mutations are more frequent in the advanced stages or cancer subtypes with 
aggressive behavior (e.g., triple negative or HER2- amplified breast cancers) 73–75; 
whereas, in tumors with low mutation rates, p53 is often inactivated by alternative 
mechanisms 67. 
In contrast to other tumor suppressor genes, most TP53 mutations in human cancer 
are missense substitutions (75%); whereas, frameshifts, deletions, amplifications (9%), 
nonsense (7%) and silent mutations (5%) are rare 76. 
Typically, mutations occur in hotspots within the DBD of the protein 77 and in 90% 
of cases are missense mutations; in contrast, outside DBD, missense mutations are 
only the 40% and the majority are nonsense or frameshift mutations. 
About 25% of the missense mutations are C:G > T:A substitutions that occur in CpG 
dinucleotides in codons that are essential for the structure and the chemical bond be-
tween p53 and DNA REs 78. CpG dinucleotides are prone to be mutated 79; indeed, 
among all residues mutated in the DBD, 3 CpG dinucleotides (175, 248 and 273) rep-
resents alone 60% of CpG mutations and another five (196, 213, 245, 282, and 306) 
residues account for 26% of these variations. Other CpG sites are detected in tumors 
because substitution at these residues does not generate a dysfunctional protein. 
Generally, missense mutations can have two effects on p53 protein: either interfere 
with the contact between p53 and DNA REs (contact mutant) (e.g., R248 and R273) 
or alter protein conformation and perturb the structure of the DNA-binding surface 
(conformation mutant) (e.g., R175, G245, R249 and R282) 22,80. 
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All TP53 mutations detected in tumors induce the loss of tumor suppressor function 
(“loss of function”); in addition, some mutations confer oncogenic features to p53 
protein (“gain of function”) that contribute to tumor initiation and progression. To 
sum up, p53 mutations can contribute to cancer progression in three different ways: 
1. loss of p53 wild-type (wt_p53) function. 
2. Dominant-negative effect (DNE) either on p53 wt allele in case of heterozy-
gous cells or on other p53 family members (p63 and p73) 81. As previously 
described, to activate the transcription of its target genes, p53 forms tetramers 
that are dimers of dimers; mut_p53 together with wt_p53 forms tetramers, 
which are not functional, thus inhibiting wt_p53 function. 
3. Gain of oncogenic functions (GOF). This feature was discovered when the 
introduction of mut_p53 into p53 null cells give rise to a new phenotype 82. 
Moreover, in vivo experiments demonstrated that mice expressing mut_p53 dis-
play a tumor profile more aggressive (e.g. higher incidence of metastasis) than 
p53 null or wt_p53 mice 83–86. GOF confers mut_p53 the ability to interact 
with other proteins, such as transcription factors (TFs) or chromatin-modify-
ing proteins, that are not partners of wt_p53 87,88. 
There are several downstream effects of GOF mut_p53: it promotes invasion 
and motility by enhancing transforming growth factor b (TGF-b) 89, epidermal 
growth factor receptor (EGFR) 90,91 and MET 92–94 pathways and by enhancing 
integrin/RCP recycling 93,94. Mut_p53 regulates apoptosis and autophagy 
through both cytoplasmic and mitochondrial pathways 95–97. Mut_p53 also reg-
ulates genomic instability 98, chemoresistance 99, metabolic alteration 100, accu-
mulation of reactive oxygen species 101, enhanced cell survival 102 and prolifer-
ation. 
Recently, studies identified new activities of mut_p53, such as a role in cell 
reprogramming 103,104 with the ability to dedifferentiate somatic cells into plu-
ripotent stem cells and thus initiating tumor formation 105,106. 
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1.1.4. Clinical implications 
Different studies have investigated the impact of TP53 mutations on patient outcome, 
but the results have been heterogeneous and contradictory. In some studies, TP53 
mutations have been correlated with a shorter survival or a poorer response to treat-
ment 76; in breast cancer, TP53 mutations correlated with more aggressive gene expres-
sion profiles (e.g. basal) and mutations within the DBD were associated with a worse 
prognosis compared with mutations outside DBD 107; however, it was no clear whether 
TP53 was an independent prognostic factor, and which specific mutations caused a 
worse prognosis 108. 
From a therapeutic point of view, based on the evidences that mut_p53 confers more 
aggressive behaviors to tumor cells, mut_p53 is a promising molecular target for newer 
anti-tumor therapies 109–111, as supported by two studies on transgenic mice models 
112,113. 
 
 
Figure 3: Strategies to target mut_p53. They include promotion of mut_p53 degradation through the proteasome 
and autophagy pathways, restoration of wt_ p53 activity, interference with the interaction between mut_p53 and other 
proteins, and interference in signaling pathways downstream of mut_p53. Adapted from 114. 
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The second strategy to inhibit mut_p53 activity targets its downstream targets of 
mut_p53. For instance, RETRA is a small molecule destabilizing p73-mut_p53 inter-
action, resulting in p73 release and restoration of its anti-tumor suppressor activity 115. 
Alternatively, inhibition of cholesterol synthesis 100 or inhibition of EGFR, MET or 
MAPK pathways 89–91,93, all mut_p53 downstream signaling pathways, can also exert an 
anti-tumor effect. 
The third strategy to inhibit mut_p53 function is to restore wt_p53 protein folding. 
For example, some compounds (e.g., PRIMA-1, CP-21298, SCH29074) interact with 
DBD, promote wild-type folding and restoration of p53 function 116–118. As previously 
mentioned, the ion Zn(2+) is necessary to wt_p53 folding 26, in some conformational 
mutants increasing Zn(2+) levels partially restores the wild-type conformation 119,120. 
The last example is a class of molecules (e.g., Phikan083, PK7088) designed to target 
a single conformational mutant, Y220C mut_p53, and able to restore wt_p53 confor-
mation and activity 121,122. 
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1.2. Non-coding RNAs 
Non-coding RNAs (ncRNAs) are RNA molecules that do not encode for proteins. 
There are two kinds of ncRNAs: infrastructural and regulatory 123. Infrastructural ones 
are important for RNA processing and translation: transfer RNAs (tRNAs), ribosomal 
RNAs (rRNAs), small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs). 
The regulatory ncRNAs regulate gene expression at the transcription level, RNA pro-
cessing or translation: micro RNAs (miRNAs), small interfering RNAs (siRNAs), Piwi-
interacting RNAs (piRNAs) and long non-coding RNAs (lncRNAs). Based on their 
size, ncRNAs could be classified as: 
• small ncRNAs: long 20-30 nucleotides (nt); 
• long ncRNAs: longer than 200 nt and up to 100 kb 124,125. 
Since the discovery of siRNAs, later on of microRNAs, and now with the wave of long 
ncRNAs, many researchers realized that throughout metazoan evolution, despite a 
quite constant number of proteins, the size of genomes expanded and the transcribed 
portion of it, which is 98% in the human genome. Regulatory ncRNAs, but not only 
126, seem to have played an important role during human evolution 127. Without no 
surprise, ncRNAs not only are involved in evolution and development, but also in 
diseases, such as cancer and neurodevelopmental disorders 128. 
 
1.2.1. Small ncRNAs  
Three main classes of small regulatory RNA exist and they all are processed from 
longer to shorter mature transcripts (Figure 4). 
miRNAs are the most abundant regulatory small RNAs 129, they are about 22nt long, 
and the most current annotation includes 2588 human miRNAs 130. miRNA genes are 
transcribed by RNA polymerase II to generate the primary miRNAs (pri-miRNAs). 
Like protein coding gens, transcription of miRNAs genes is finely regulated 131–135; like-
wise, the maturation from pri-miRNAs to mature miRNA (Figure 4) 136–139 and export 
from the nucleus to the cytoplasm 140–144. Mature miRNAs are eventually loaded onto 
an AGO protein to form the RNA-induced silencing complex (RISC), a ribonucleo-
protein complex that mediates all RNA-silencing pathways 145,146. RISC complex rec-
ognizes targets depending on complementarity between mature microRNA and the 
3’UTR of target mRNA and reduces translation or induces the degradation of mRNA 
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transcript, depending on the degree of base-pairing complementarity between the 
mRNA and the first 5’ 8 nucleotides of mature microRNA (seed region) 132. Since the 
site of interaction between miRNA and mRNA is long only 6–8 bp, each microRNA 
has the potential to target multiple different mRNAs 147; indeed, it has been estimated 
that overall miRNAs regulate about one-third of human protein-coding genes 148. miR-
NAs are typically well conserved throughout evolution and are key regulators of sev-
eral cellular functions and development, and their misregulation could cause several 
human diseases, including cancer 149. 
 
 
Figure 4: Biogenesis of small ncRNAs. Adapted from 150. 
 
Piwi-interacting RNAs (piRNAs) are 24-30 nt long, and their primary function is to 
silence active retrotransposon elements (TEs) in the germline cells 150–152. Unlike mi-
croRNAs, piRNA sequences are not conserved; however, genomic positions of 
piRNA clusters are conserved in mammals 153–155. piRNAs are produced through a pri-
mary processing pathway, which generates an initial pool of piRNAs, that on its turn 
is amplified through a ping-pong pathway that amplifies only piRNAs that target active 
transposons. piRNAs function is not Dicer-dependent 156 but relies on PIWI proteins 
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to form an active piRNA-induced silencing complex (piRISC) that recognizes and si-
lences complementary TE RNA targets 157–159. 
 
siRNAs are endogenously expressed in plants; whereas, in human there are few exam-
ples of endogenous siRNAs. XIST-TSIX duplex is processed by Dicer to generate 
siRNAs which are required for the repressive chromatin modification on the inactive 
X chromosome 160. Antisense pseudogene transcripts that pair with cognate gene 
mRNAs. At the same time, human cells can use miRNA processing and RISC com-
plexes to generate siRNAs when short hairpin RNAs (shRNA) are transfected into the 
cell, which is a common biotechnology strategy to silence protein expression for re-
search purposes. 
 
1.2.2. LncRNAs 
LncRNAs are 200 nt up to 100 kb long 124,125. The most updated human ENCODE 
annotation lists more than 28000 different lncRNAs, which are expected to rise even 
more with the widespread usage of deep sequencing approaches 161. LncRNAs are 
transcribed by PolII, they can be either spliced or not, usually polyadenilated, and they 
are less expressed but in a more tissue-specific manner than the protein coding coun-
terpart or miRNAs 162. Typically, lncRNAs are present across several species but are 
poorly conserved 163–166. 
Classification of lncRNAs is based on their genomic location relative to protein-coding 
genes: 
1. Intergenic lncRNAs: do not overlap protein-coding genes and have independ-
ent transcription units, they are also called long intergenic non-coding RNAs 
(lincRNAs) 167,168. They have chromatin signatures of transcribed genes 
(H3K4me3 at the promoter and H3K36me3 along the transcribed length). 
They are transcribed by RNA polymerase II, spliced, capped and polyadenyl-
ated, and typically they are long 1 kb 169. They are expressed in a tissue-specific 
manner more than protein-coding genes 162,170,171 and conserved across multiple 
vertebrate species 170. Among lncRNAs, lincRNAs are the most abundant (e.g. 
XIST, H19 and MALAT1). 
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2. Intronic lncRNAs: although it is well known that introns harbor small ncRNAs 
(snoRNAs and miRNAs); recently, many lncRNAs have been identified within 
introns of protein-coding genes.  
3. Antisense lncRNAs: are transcripts that intersect any exon of a protein-coding 
gene but are transcribed in opposite orientation. About 87% of all transcripts 
(coding and non-coding) overlap with antisense lncRNAs 170, and about 32% 
of the lncRNAs belong to the antisense subtype. Antisense are mostly enriched 
around the 5’ (promoter), or 3’ (terminator) ends of the sense transcripts, typ-
ically they are not spliced or polyadenylated.  
4. Sense lncRNAs: share any exon of protein-coding genes and are transcribed in 
the same orientation, but do not encode for proteins 172.  
 
Like miRNAs, lncRNAs are involved in a great variety of biological processes 123,173 
(e.g. transcription 174,175, splicing 176,177, translation 178,179, protein localization 180,181, cellu-
lar structure integrity 182,183, imprinting 184–186, cell cycle 187,188, apoptosis 189,190, stem cell 
pluripotency 191 and reprogramming 192 and heat shock response 193–195); but unlike 
other ncRNA classes, lncRNAs have several different mechanisms of action 124. For 
example, lncRNAs are predominately localized in the cell nucleus and bound to chro-
matin 162, suggesting a role in regulation of gene transcription. They can work both in 
cis, regulating the expression of genes closed to lncRNA locus, and in trans, regulating 
the expression of distant genes. To this aim, lncRNAs recruit chromatin remodeling 
complexes (e.g. Polycomb) and guide them to specific genomic loci thus affecting gene 
expression 196,197. XIST (X inactive-specific transcript) acts in cis and is involved in ep-
igenetic X chromosome inactivation 198,199. It is highly expressed only by the chromo-
some that will be inactivated, and it coats the chromosome serving as a guide for the 
recruitment of the Polycomb repressive complex 2 (PRC2), a member of the chroma-
tin-modifying complexes that trimethylates histone H3 at lysine 27, which represses 
expression of the targeted chromosome 200. Another example of lncRNAs regulating 
gene expression happens during body segmentation. Many lncRNAs are transcribed 
in the intergenic regions between Homeobox transcription factor (HOX) genes 175: 
HOTTIP recruits a protein complex that trimethylates lysine residue 4 (K4) of histone 
H3 to activate the HOXA gene cluster 201; whereas, HOTAIR (HOX antisense inter-
genic RNA) represses the transcription of HOXD in trans guiding PRC2 and LSD1, 
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which is an H3K4 demethylase 202. Finally, LincRNA-p21 is located upstream of 
CDKN1A gene, which encodes p21 protein, a known downstream target of wt_p53. 
LincRNA-p21 expression is directly regulated by wt_p53 and itself enables wt_p53 ma-
chinery to increase CDKN1A expression levels 189,203. 
LncRNAs can also decoy proteins and RNAs preventing them to act. For instance, 
PANDA sequesters and inhibits the nuclear transcription factor NF-YA, which actives 
the apoptotic program after DNA damage. Thus, PANDA promotes cell survival 204. 
Similarly, Gas5 (growth arrest-specific 5) binds to the DNA-binding domain of the 
glucocorticoid receptor, inhibiting glucocorticoid-regulated transcription in growth-
arrested cells 205. At the same time, PTENP1 is PTEN pseudogene, it does not encode 
for Pten protein, but its 3’UTR can bind miRNAs that regulate PTEN expression, 
acting as a miRNA sponge and ultimately increasing Pten expression levels 206. Simi-
larly, linc-RoR (lincRNA regulator of reprogramming) is a sponge of miR-145, which 
in its turn regulates the expression of Oct4, Sox-2, Nanog, three transcription factors 
important in cellular reprogramming and the maintenance of pluripotency 192. 
Finally, lncRNAs can serve as central scaffold in which multiple proteins assemble. 
The scaffold archetype is lincRNA NEAT1 (nuclear enriched abundant transcript 1), 
an essential architectural component of paraspeckles, the nuclear domains implicated 
in mRNA nuclear retention. NEAT1 participates in PSP1 and p54 dimer formation 
and localized them to the paraspeckles 207. Another example is HOTAIR, which binds 
to two E3 ubiquitin ligases with RNA-binding domains (Dzip3 and Mex3b) and with 
the relative substrates (Ataxin-1 and Snurportin-1), facilitating their ubiquitination and 
degradation 208. 
 
1.2.3. LncRNAs and cancer 
By genome-wide association studies (GWAS) it has been discovered that 80% of can-
cer-associated SNPs (single nucleotide polymorphisms) are inside non-coding regions 
of the genome 209. Many of these loci may be transcribed into ncRNAs and collaborate 
to tumorigenesis and metastasis. LncRNAs can be either tumor suppressors or onco-
genes. Moreover, next-generation sequencing (NGS) revealed that thousands of 
lncRNAs are aberrantly expressed or mutated in various cancers 210. 
Below, we report some examples of lncRNA involved in human cancers, in particular, 
focusing on breast and ovarian cancer Figure 5 211. 
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Figure 5: LncRNAs associated with cancer. Adapted from 211. 
 
HOTAIR is frequently overexpressed in human cancer (breast, ovarian, colorectal, 
hepatocellular, pancreatic, renal, gastrointestinal, non-small cell lung carcinomas) 212–
216, it increases tumor invasiveness and metastasis and is associated with poor prognosis 
in several cancers 217. As described above, it silences the expression of target genes 
through the induction of epigenetic modifications and is involved in the assembling of 
E3-ubiquitin ligases during protein degradation 175. HOTAIR is required for the viabil-
ity of breast cancer cells and estradiol regulates its expression via the estrogen receptor 
pathway 218. 
 
ANRIL is upregulated in leukemia, breast and prostate cancers 219. It is an antisense 
transcript of CDKN2B (cyclin-dependent kinase inhibitor 2B) gene and controls cell 
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proliferation and senescence via the epigenetic regulation of its neighboring tumor 
suppressor gene CDKN2A/B 220. It is also required for the repression of tumor sup-
pressors p15. 
 
MALAT1 also call NEAT2 (nuclear enriched abundant transcript 2) is frequently 
overexpressed in human cancer (lung, bladder, breast, colorectal, liver, prostate and 
ovarian cancer) 221, correlated with increased cell proliferation and metastasis, by de-
regulating N-cadherin and E-cadherin expression 222. It is post-transcriptionally pro-
cessed to produce a short RNA; whereas, the long form is localized to nuclear speckles 
where modulates the alternative splicing by regulating the level of phosphorylated 
splicing-associated serine-arginine (SR) proteins. It is a potential biomarker and thera-
peutic target. 
 
H19 is one of the first lncRNAs discovered and has a crucial role in embryonic devel-
opment and tumorigenesis (liver, breast, colorectal, esophageal, lung, pancreatic, gas-
tric, bladder and cervical carcinoma) 223–226. It is a decoy for miRNAs and interacts with 
transcriptional repressors to induce the silencing of its target genes. It is the precursor 
of miR-675, which inhibits p53, which in turn represses H19. It promotes tumorigen-
esis and metastasis, and it is expressed in response to hypoxic stress and epithelial-to-
mesenchymal transition (EMT). Its expression leads to the activation of genes involved 
in angiogenesis, cell survival, proliferation.  
 
XIST it is overexpressed in leukemia and ovarian cancer and regulates genes expres-
sion by interacting with PRC1, PRC2 227. Its knockdown results in enhanced sensitivity 
to Taxol 228. 
 
As described in the first chapter, p53 is among the most important transcription fac-
tors and it is finely regulated by several mechanisms that involve transcription, trans-
lation, and post-translational modifications. LncRNAs both regulate p53 expression 
levels and are downstream targets of p53 229. Among the lncRANs that regulate p53, 
we mention MALAT1 (repressor of TP53 transcription) and MEG3 (activator of TP53 
transcription). Among lncRNAs that are p53 effectors, there are lincRNA-p21, 
PANDA, H19, loc285184, and lncRNA-Ror. 
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1.3. Ovarian cancer 
1.3.1. Ovarian cancer epidemiology 
Ovarian Cancer (OvCa) is a relatively uncommon tumor, accounting for about 1.3% 
of newly diagnosed tumors in 2017 in the United States; yet, it represents the 5th most 
common cause of cancer death in women in Western countries and the leading among 
gynecological cancer 230–232. Typically, OvCa is diagnosed in postmenopausal age, being 
the majority (>80%) of cases diagnosed in women over 50 years with a median age at 
diagnosis of 63 years 230. Overall survival rate at 5 years is 46,5%, greatly depending on 
tumor stage; indeed, in the rare case in which OvCa is diagnosed in local stage (local-
ized to the ovary), the 5-years survival is 92.5%, whereas when it has been diagnosed 
in advanced stage (dissemination outside the ovaries) the survival is only 28.9%. Un-
fortunately, only the 15% of cases are diagnosed at a local stage (tumor confined to 
primary site), 20% at regional stage (tumor spread to regional lymph nodes) and the 
majority (60%) at a distant stage when cancer metastasize 230. Moreover, death rates 
increase with age 233 and in the last 30 years, the overall 5-years relative survival rate 
had only a very modest increase (2%-4%) 234. 
 
Many risk factors have been identified to be associated with OvCa. Among environ-
mental risk factors, the principal is the life-long number of ovulations; indeed, nullip-
arae have greater risk than multiparare; likewise, longer reproductive life (early menar-
che and late menopause) increases OvCa risk. On the contrary, the use of oral contra-
ceptive pill, tubal ligation, breastfeeding and suppression of ovulation are all protective 
against OvCa 235. Two hypotheses explain the association between number of ovula-
tions and OvCa risk. The first is the “incessant ovulation” hypothesis, which holds 
that the number of ovulatory cycles increases the rate of cellular division associated 
with the repair of the surface epithelium after each ovulation, thereby increasing spon-
taneous mutation 236,237. The second hypothesis, namely the “gonadotropin hypothe-
sis”, focuses on the role of gonadotropins, such as luteinizing hormone and follicle-
stimulating hormone, hypnotizing that OvCa develops in response to an excessive 
stimulation of ovarian tissue by these hormones 238. Other environmental risk factors 
are obesity 239–241, endometriosis 242–244, the use of postmenopausal hormone therapy 
245–247 and the use of talcum powder 230,235,248,249. 
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Regarding OvCa genetic risk, the most critical factor is a positive familial history of 
OvCa; indeed, approximately 20% of OvCa are familial, and women with a first-degree 
relative with OvCa have a risk to develop OvCa twofold higher than women with no 
family history 250. The single most common genetic mutation associated with OvCa is 
the mutation of BRCA1 or 2 genes. Both mutations are highly penetrant 251. In partic-
ular, a mutation in BRCA1 increases the lifetime risk of 15-45% and a BRCA2 muta-
tion of 10-20%. These women tend to develop the disease earlier (10 years before) 
than the women with non-hereditary OvCa 235, and their tumors metastasize more fre-
quently to the viscera; whereas, sporadic ovarian cancer remains confined to the peri-
toneum. At the same time, OvCa risk is also due to low-moderate penetrance variants, 
which explain about 80% of the familial risk and located in intergenic or in protein 
coding genes (e.g. BRIP1 252 and RAD51 253,254). 
 
1.3.2. Ovarian cancer histology and pathogenesis 
OvCa is a highly heterogeneous group of malignant tumors that may arise from germ 
cells, stromal or epithelial cells, which per se represents 90% of OvCas (Epithelial 
Ovarian Cancer – EOC). Based on histopathology and molecular genetic alterations, 
EOCs are divided into five main subtypes 235,255: 
• endometrioid, 
• clear cell, 
• mucinous 
• high-grade serous, 
• low-grade serous. 
 
Endometrioid OvCas are about 10% of all OvCas, they are typically diagnosed at early 
stage and have low grade. Such as colorectal and stomach cancers, also inherited en-
dometrial cancer is commonly associated with Lynch syndrome, a condition caused by 
germline pathogenic variants in the highly penetrant mismatch repair genes MLH1, 
MSH2, MSH6, PMS2, and EPCAM 256. Both endometrioid cysts and endometrioid 
OvCas have a mutation in ARID1A 257. 
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Clear cell OvCa account for 5% of OvCas, and it is more frequent in Japanese women. 
This tumor type is strongly associated with endometriosis and it is frequently mutated 
in ARID1A 257. Clear cell OvCas frequently develop chemoresistance with a worse 
patient outcome in advance stages compared to than serous OvCa. 
 
Mucinous OvCa accounts for about 10% of OvCas and have a different natural history 
from other histologic types in terms of presentation, response to therapy and outcome. 
Commonly, patients with a mucinous OvCa are diagnosed at early-stage and have an 
excellent prognosis, whereas when diagnosed in advanced disease the outcome is poor. 
Mucinous OvCas are characterized by the overexpression of KRAS, whereas 
BRCA1/BRCA2 and TP53 typically are not mutated 258, which all suggest that develop 
along a separate pathway. 
 
Low grade serous OvCa (LGSOC) (<5% of EOC 259,260) typically arises at younger age 
and has mild to moderate cytologic atypia and low mitotic rate. LGSOC tends to have 
a better survival than HGSOC; even though, LGSOC do not respond to traditional 
chemotherapy 261,262. 
 
The majority of epithelial OvCas (80%) belong to the high-grade serous ovarian carci-
noma (HGSOC) subtype, which is the most lethal among the 5 subtypes. HGSOC 
presents severe nuclear atypia and high mitotic rates. Gene expression profiling iden-
tified four HGSOC molecular subtypes of biological and clinical importance: mesen-
chymal (worse prognosis), proliferative, differentiated and immunoreactive (better 
prognosis) 263.  
Recent findings highlighted that epithelial OvCas do not originate from ovaries, but 
from other gynecological tissues and involve the ovary secondarily 264. For example, 
clear cell and endometrioid OvCas develop from endometriotic cysts associated with 
endometriosis 235, and mucinous OvCa from transitional cell nests at the tubal-meso-
thelial junction 265. Concerning HGSOC, histopathologic examinations of fallopian 
tubes removed from BRCA 1 and 2 carriers showed hyperplastic and dysplastic lesions 
that are characterized by higher expression and mutations of TP53 (p53 signature) and 
serous tubal intraepithelial carcinoma (STIC) 266,267. Evolutionary analyses revealed that 
p53 signatures and STICs are precursors of OvCas and identified a window of 7 years 
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between the development of STIC and initiation of ovarian carcinoma, with metastases 
following rapidly after that 268. 
 
Another classification divides epithelial OvCa into two types 235,269,270, based on their 
molecular expression profile: 
- Type 1 includes: low-grade serous, endometriosis-related subtypes (endome-
trioid, clear-cell and seromucinous), mucinous and malignant Brenner tumors. 
They are characterized by a young age at diagnosis, an indolent disease course 
with a prolonged overall survival time 271 and a relative resistance to standard 
platinum and Taxol chemotherapy 236. These tumors show genomic stability 
and mutations in KRAS, BRAF, ERBB2, PTEN, PIK3CA and ARID1A genes 
that occur early in the tumorigenesis. 
- Type 2 comprises aggressive tumors: high-grade serous, high-grade endome-
trioid, malignant mixed mesodermal tumors and undifferentiated tumors. 
These tumors usually present with a symptomatic bulky stage III or IV disease 
and ascites. They are most prevalent in postmenopausal women, are initially 
very chemosensitive to platinum chemotherapy, however, they have a poor 
outcome 236. They are usually associated with TP53 mutations (97% of 
HGSOC have a TP53 mutation) 272,273, mutations are found in tumors of all 
stages, suggesting that they were originated in an early event in the progression 
of the disease 274. Approximately 20% of these tumors carries a somatic o 
germline mutation in BRCA1/2, amplification of the AKT2 and the phospha-
tidylinositol 3-kinase genes 275. 
 
1.3.3. Mechanisms of ovarian cancer metastasis 
OvCa cells primarily disseminate within the peritoneal cavity and only rarely spreads 
through the vasculature 236. 
In the first steps of metastasis, OvCa cells undergo to EMT, which loses the attach-
ment of epithelial cells from the basement membrane and neighboring cancer cells. 
Fundamental in this process is the loss of E-cadherin, a membrane glycoprotein lo-
cated at cell adherens junctions 276,277. E-cadherin connects through a- and b- catenin 
to the actin microfilaments within the cytoplasm, anchoring epithelial cells to each 
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other. In OvCa, E-cadherin expression in metastatic cancer cells (i.e. ascites and met-
astatic implants) is lower than in primary tumor 278, and its low expression predicts 
poor patient survival 279. During EMT occurs a “cadherin-switch” which consists of 
E-cadherin downregulation, N-cadherin and P-cadherin up-regulation 280–282. This sit-
uation allows cancer cells to survive under hypoxic conditions 283 and activate mesen-
chymal signaling by interaction with surrounding stromal cells: on tumor cells, integ-
rins activate matrix metalloproteinase (MMP)-9, which cleaves the E-cadherin ectodo-
main and contribute to the loosening of cell-cell adhesion thus spreading transformed 
cells as single cells or spheroids into ascites 284. 
In the second step of metastasis, cancer cell spheroids, which detached from the pri-
mary tumor, float in the peritoneal fluid. In the spheroids, cancer cells maintain a mes-
enchymal phenotype 285, keeping repressed E-cadherin and MMP-2; moreover, E-cad-
herin loss leads to transcriptional up-regulated of fibronectin receptor a5b1-integrin, 
facilitating the adhesion of OvCa cells to the secondary site 286. 
Once cell spheroids adhere to peritoneum, OvCa cells revert to their epithelial pheno-
type to respond to paracrine oncogenic growth factor. In particular, OvCa cells invade 
the mesothelium, a monolayer of mesothelial cells attached to a basement membrane 
predominantly composed of collagen types I and IV, fibronectin and laminin 287. Mes-
othelium covers all organs within the peritoneal cavity 288,289. Integrins and CD44 (the 
principal cell surface receptor for hyaluronic acid) are the principal mediators of OvCa 
metastasis in the mesothelium 290. When OvCa cells attach to mesothelial cells, cancer 
cells up-regulate MMP-2, that cleaves fibronectin and vitronectin in smaller fragments, 
which are even better ligands of a5b1 and aVb3 integrins 291–296. Moreover, a recent 
study demonstrated that cancer-associated mesothelial cells facilitate initial metastatic 
colonization of OvCa cells, secreting fibronectin and providing access to the submes-
othelial extracellular matrix 297. 
After OvCa cells implanted on omentum or peritoneum, cells start to replicate and 
when reaching a certain size, they require new blood vessels to provide nutrients and 
support their growth. Inflammation and injury stimulate the peritoneal cells and their 
associated immune and stromal cells to release cytokines such as inteleukin1 (IL)-1, -6 
and -8 that subsequently increased the secretion of vascular endothelial growth factor 
(VEGF) by cancer cells 298. VEGFs stimulate vascular and lymphatic endothelium to 
form new blood and lymphatic vessels and regulate their permeability. 
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Lastly, microarray studies 299,300, comparative genomic hybridization 301 and high-reso-
lution single-nucleotide polymorphism analysis 302 demonstrated similar genetic alter-
ations in primary ovarian tumors and their respective metastases, further supporting 
the passive mechanism of OvCa metastasis. 
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1.4. Breast cancer 
1.4.1. Breast cancer epidemiology 
Breast cancer (BC) represents the most common non-skin malignancy in women, and 
it is the second cause of cancer mortality. In the United States in 2017, more than 
250,000 new BC cases and 40,000 BC-related deaths are estimated 303, indicating that 
fewer than one out of six women diagnosed with BC die for the disease 304. In recent 
years, the mortality rate has decreased, especially in younger age groups, because of 
improved treatment and earlier detection 234,305. BC incidence increased after introduc-
tion of mammography screening and continues to grow with the aging of the popula-
tion 306. Indeed, a 70-years-old woman has a chance of being diagnosed with BC 10 
times higher than a 30-years-old woman 307. 
 
Regarding the environmental risk factors, a relevant one is the exposure to estrogen, 
both endogenous (e.g., nulliparity, early menarche and late menopause, older age at 
first birth) and exogenous (e.g., use of combination estrogen-progesterone hormones 
after menopause) 306,308 that increases growth of breast cells, facilitating the develop-
ment of BC. Other environmental risk factors include, alcohol consumption, obesity 
and exposure to ionizing radiation during puberty 309. 
 
Concerning the genetic factors, women with family history of BC have an increased 
risk 310,311: risk is doubled if a first-degree relative is affected similarly to OvCa, germline 
mutations of BRCA genes are typically occurring in 5-10% of all BC 312–314. These mu-
tations are high penetrant, with BC diagnosis occurring at a younger age, and with a 
lifetime risk of 55%-65% and 45%-47% for BRCA1 and BRCA2 mutation carriers, 
respectively 256,315. 
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1.4.2. Breast cancer histology and pathogenesis 
BC is a highly heterogeneous disease in terms of histopathological and biological fea-
tures and clinical outcome 316.  
 
The histopathological classification is based on the diversity of the morphological fea-
tures of the tumors. The first major histopatological difference is between in situ and 
invasive (i.e. infiltrating) carcinomas 307,317,318. In situ BC is sub-classified in: 
• Ductal (DCIS), in which breast epithelial cells that connect the lobules to the 
nipple have become cancerous, but do not invade the basal membrane. It rep-
resents the 83% of in situ cases, and even though is nonlethal, it can develop 
into a deadly invasive form 319,320. DCIS is frequently identified through mam-
mographic screening programs, and it is usually treated with surgical excision 
304. 
• Lobular (LCIS), in which cancerous cells are found in the breast lobules. It is 
the 13% of in situ cases, and generally is not a precursor of invasive cancer. 
 
The majority of BCs (80%) belong to the invasive type, in which tumors invade the 
basal lamina and grow into surrounding breast tissue. Invasive BC can be sub-classified 
in 318: 
• Infiltrating ductal (IDC), that is the most common, comprises 70-80% of all 
cases. Based on the levels of nuclear pleomorphism, glandular/tubule for-
mation, and mitotic index, IDC is further sub-classified as well-differentiated 
(grade 1), moderately differentiated (grade 2) or poorly differentiated (grade 3) 
321,322. 
• Invasive lobular, 
• Mucinous, 
• Tubular, 
• Medullary, 
• Papillary. 
 
A more recent classification scheme is based on the immunohistochemical characteri-
zation of hormone (estrogen -ER- or progesterone –PR-) receptor status, Her2 protein 
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overexpression or HER2 gene amplification and the proliferative fraction (Ki-67) 
316,323. Therefore, a tumor can be considered 324: 
• ER and PR positive, if it has 1% or more immunoreactive cells. The higher 
is the number of positive neoplastic cells, and the larger is the expected benefit 
of endocrine therapies. 
• HER2 positive, if it overexpresses Her2 in more than 10% of invasive tumor 
cells, or show HER2 gene amplification. They are candidates for Trastuzumab 
treatment. 
• Triple negative, if it is ER, PR and HER2 negative. They are more common 
in premenopausal women in BRCA1 mutant carriers 325. They have the shortest 
survival, because contain high number of cancer steam cells 326 and also be-
cause there are not targeted therapies 327. 
 
Hierarchical clustering analysis of gene expression identified different heterogeneous 
subtypes of BC with different distinct molecular patterns correlated with a different 
prognosis 328–331. Perou et al. identified four major BC subtypes: 
• Luminal: are hormone receptor-expressing cancers, and their gene expression 
patterns remind the luminal epithelial component of the breast 328. In particu-
lar, they express luminal cytokeratins 8 and 18, ER and genes associated with 
ER activation, whereas mutations in TP53 are rare (<20%) 328–330. Luminal BCs 
are often grade I and typically carry a good prognosis. They are treated with 
hormone therapy since several reports have demonstrated that ER-positive tu-
mors respond poorly to conventional chemotherapy 332. It represents the most 
common subtype of BC and is in turn subdivided in: 
o Luminal A: have, in general, higher expression of ER-related genes 
than luminal B. They are slow-growing and low-aggressive and can be 
treated with endocrine therapy alone 333,334. 
o Luminal B: have higher expression of proliferative genes and tend to 
be a higher grade than luminal A, for these reasons patients benefit 
from chemotherapy added to endocrine therapy 334,335. 
• HER2-enriched: are hormone receptor-negative (low expression of ER and 
related genes) and have an overexpression or amplification of HER2 gene 329. 
It has a high proportion of TP53 mutations (40-80%), and since it is typically 
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high grade and poorly differentiated, this subtype carries a poor prognosis 329. 
It can be treated with molecularly targeted agents, such as the anti-HER2 mon-
oclonal antibody Trastuzumab. 
• Basal-like: it is so-called because the expression pattern mimicked that of the 
basal epithelial cells 328. This subtype lacks expression of ER and related genes, 
low expression of HER2, strong expression of basal cytokeratins 5,6 and 17 
and expression of proliferation-related genes. They are typically BRCA and 
TP53 mutated. Basal-like tumors have aggressive features, are generally high 
grade and carries a poor prognosis 329,330. Since they are triple-negative for the 
receptors (ER, PR, and HER2), conventional targeted therapies are not used, 
and the unique choice is chemotherapy.  
To classify BC samples in these three groups, a gene expression assay has been devel-
oped: PAM50 (prediction analysis of microarray) which is a 50-genes signature able to 
differentiate the molecular subtype using gene expression on FFPE tissue 336. 
 
1.4.1. Mechanisms of breast cancer metastasis 
Metastasis is of great importance in BC, because it accounts for the majority of cancer 
deaths. To metastasize, BC cells have to perform an extraordinarily complex process 
that comprises a series of sequential steps collectively termed metastatic cascade (Fig-
ure 6). All these steps must be executed while tumor cells avoid immunological re-
sponses and survive to apoptotic signals 337. 
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Figure 6: The Metastasis Cascade. During metastatic progression, tumor cells exit from their primary sites of 
growth (local invasion, intravasation), translocate systemically (survival in the circulation, arrest at a distant organ site, 
extravasation), and adapt to survive and thrive in the foreign microenvironments of distant tissues (micrometastasis for-
mation, metastatic colonization). Adapted from 338. 
 
Local invasion: in the first step, BC cells have to separate from the primary tumor 
and invade the surrounding tumor-associated stroma. To do this, tumor cells must lose 
their cell-to-cell adhesion and cell-matrix (ECM) contacts. The cadherin family has a 
predominant role in this step 339: E-cadherin maintains the cell-cell junctions, and its 
downregulation determines the outgrowth of metastatic BC cells 340, whereas N-cad-
herin is closely associated with mesenchymal cells and related to EMT 341. EMT plays 
an important role in stroma invasion, because it induces the production of metallopro-
teinases and other proteolytic enzymes that degrade the ECM 342,343. Once the BC cells 
invade the stroma, they adhere to the ECM through the integrins 344 that interact with 
fibronectin, laminin, collagen, fibrinogen, and vitronectin 339.  
 
Intravasation: during this step, the BC cells enter into the lumina of blood or lym-
phatic vessels. Intravasation can be facilitated by molecular changes that promote the 
ability of carcinoma cells to cross the pericyte and endothelial cell barriers that form 
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the walls of microvessels. For example TGFb enhances mammary carcinoma intrava-
sation, ostensibly by increasing carcinoma cell penetration of microvessel walls or aug-
menting invasiveness more generally 345. This passage is strongly influenced by the 
structural feature of tumor-associated blood vessels. In contrast to non-cancerous 
blood vessels, these are tortuous, prone to leakiness and in a state of continuous re-
configuration 346. Since the interaction between adjacent endothelial cells are weak, and 
there are not pericyte, the intravasation is facilitated. 
 
Survival into the circulation: once BC cells have intravasated into the lumina of 
blood vessels, they can disseminate through the circulation as circulating tumor cells 
(CTCs) 347,348. They represent “metastatic intermediates” between primary tumors and 
sites of dissemination. 
Inside the hematogenous circulation, CTCs must survive to a variety of stresses, such 
as the absence of anchorage that stimulates anoikis mechanism 349, toxic conditions 
(e.g., the high concentration of oxygen), immunological stress and collision with host 
cells 350,351.  
 
Extravasation: BC cells arrest at distant organ sites and extravasate into the paren-
chyma of distant tissues. Each tumor type typically metastatize to selected target organs 
352, which are for BC: brain, lung, bone, and liver. Once the BC cells lodge in the mi-
crovasculature of a distant organ, CTCs may initiate to growth and form a microcolony 
that can break the walls of the surrounding vessels 353. In an alternative way, BC cells 
cross the vessel wall into the tissue parenchyma in the opposite direction of what hap-
pened during intravasation. 
 
Colonization: once extravasated, carcinoma cells have to survive in the foreign mi-
croenvironment that they encounter in the parenchyma of distant tissues. The cells are 
called disseminated tumor cells (DTCs) 350. The microenvironment in the metastatic 
site is very different from that of the primary tumor and DTCs must overcome these 
differences to proliferate to eventually generate micrometastasis, macroscopic metas-
tases, which are eventually diagnosed.  
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2. Aim and strategy 
This PhD thesis stems on three central considerations: OvCa and BC share a high rate 
of TP53 mutations and high incidence of tumor metastasis; mut_p53 gain of function 
regulates tumor invasiveness and metastasis, and ncRNAs, particularly lncRNAs, are 
central players of gene regulation including wt_p53 pathway. However, there are not 
reports that investigate the role of lncRNAs in the pro-invasive phenotype of 
mut_p53. Therefore, the overall aim of this project is to investigate whether lncRNAs 
participate in the mut_p53 gain of function of HGSOC and BC. 
Our strategy was first to characterize HGSOC and BC cell models and to choose the 
best cell lines to investigate mut_p53 phenotypes. Next, we silenced mut_p53 in OvCa 
and BC cell lines and evaluated changes in invasiveness ability in in vitro assays (meso-
thelial clearance and 3D colony assay). Finally, using RNA deep-sequencing of nuclear 
long RNAs, we profiled the expression of lncRNAs in TP53_silenced cells and vali-
dated deep-sequencing results in mutant and wt_p53 cell models. Our future aim will 
be to modulate candidate lncRNAs gene expression using CRISPR activators and re-
pressors to investigate the impact on pro-invasiveness phenotype of mut_p53. 
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3. Materials and methods 
3.1. Cell lines and cultures 
Cells lines used in this project are listed in Table 1. No antibiotics were used for cell 
culture. Cells were maintained in humidified incubators at 37°C and 5% CO2 and reg-
ularly tested for mycoplasma contamination using MycoAlert detection Kit (Lonza, 
Germany). Only mycoplasma-negative cells were used for experiments. 
 
 
Cell line 
name 
Source Biological source Medium# 
Ov90  ATCC (CRL-11732™) Serous ovarian cancer MEDIUM 199, NaB, 15% FBS  
Cov318 ECACC Serous ovarian cancer DMEM, NaP, Gln, 10% FBS  
Cov504 ECACC Serous ovarian cancer DMEM, NaP, Gln, 10% FBS  
Ovcar4 NCI/DCTD Serous ovarian cancer RPMI, 10% FBS  
Ovcar8 NCI/DCTD Serous ovarian cancer RPMI, 10% FBS  
Kuramochi HSRRB Poorly differentiated ovarian cancer RPMI, 10% FBS 
Ovsaho HSRRB Ovarian adenocarci-noma RPMI, 10% FBS 
Cov362 ECACC Endometrioid ovarian carcinoma DMEM, NaP, Gln, 10% FBS  
Tov112d  ATCC (CRL-11731™) Endometrioid ovarian carcinoma  RPMI, 10% FBS 
MDA-MB-415 ATCC (HTB-128™) Breast carcinoma DMEM, 10% FBS 
BT474 ATCC (HTB-20™) Breast carcinoma RPMI, 10% FBS 
T47D ATCC (HTB-133™) Breast carcinoma DMEM, 10% FBS 
SKBR3 ATCC (HTB-30™) Breast carcinoma DMEM, 10% FBS 
SUM149PT Asterand Bioscience Breast carcinoma Ham’s F-12, hydrocortisone, insulin, 5% FBS,  
MDA-MB-231 ATCC (HTB-26™) Breast carcinoma DMEM, 10% FBS 
Hs578T ATCC (HTB-126™) Breast carcinoma DMEM, insulin, 10% FBS 
BT549 ATCC (HTB-122™) Breast carcinoma RPMI, 10% FBS 
MCF10a ATCC (CRL-10317™) Non-tumorigenic breast epithelial cell line Mammary Epithelial Cell Growth Medium, SupplementMix 
293FT Thermo Fisher Scientific Embryonal kidney DMEM, Gln, NaP, NEAA, 10% FBS  
MET-5A ATCC (CRL-9444™) Mesothelium RPMI, EGF, hydrocortisone, insu-lin, 10% FBS 
HCT116 ATCC (CCL-247™) Colorectal carcinoma RPMI, 10% FBS 
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Table 1: Cell lines used in this project. 
# ATCC (http://www.atcc.org/); ECACC (http://www.hpacultures.org.uk/collections/ecacc.jsp); HSRRB 
(http://www.jhsf.or.jp/English/hsrrb.html); NCI/DCTD (http://dtp.nci.nih.gov/branches/btb/tumor-catalog.pdf). 
§ RPMI (RPMI-1640 AQmedia), DMEM (DMEM AQmedia), MEDIUM 199, Ham's F-12, NaB (Sodium 
Bicarbonate), NaP (Sodium Pyruvate), Gln (Glutamine), NEAA (Non- Essential Amino Acids), Insulin (9.5 - 
11.5 µg/ml), Hydrocortisone (500 ng/ml) and EGF (epidermal growth factor) (10 ng/ml) were all from Sigma-Al-
drich (St. Louis. MO. USA). FBS (Fetal Bovine Serum) was from Carlo Erba. Cholera toxin 25 ng/ml; Calbio-
chem. Mammary Epithelial Cell Growth Medium and SupplementMix was from PromoCell. 
 
3.2. Lentivirus production and transduction 
Mutant TP53_silenced ovarian and breast cancer cell lines were generated by lentivirus 
transduction. Twenty-four hours before transfection, 293FT cells were plated to be 
70-90% confluence the next day. Transfections were performed using Lipofectamine 
2000 reagent (Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s 
instructions. The appropriate amount of DNA plasmids (see below) was diluted in 
Opti-MEM Medium (Gibco, Life Technologies) and added to diluted Lipofectamine 
2000 reagent. This mixture was incubated for 5 minutes at room temperature and then 
the DNA–lipid complex was transferred on cells. 
To silence mut_p53, we used two different DNA plasmids pLKO.1 puro vectors en-
coding TP53-shRNAs (TRCN0000003756 or TRCN0000003753 Sigma-Aldrich), as 
negative control we used a non-target shRNA control (SHC016; Sigma-Aldrich). For 
all constructs, we used both a stably expressing cassette or an IPTG inducible one. To 
generate viral particles, 293FT were transfected (as previously described) using one of 
the pLKO shRNA DNA vector together with ViraPower Lentiviral Packaging Mix 
(pLP1, pLP2 and pLP/VSV-G) (Invitrogen, Thermo Fisher Scientific, Eugene, OR, 
USA). Seventy-two hours later, viral supernatants were collected and transducing units 
per ml of supernatant were determined by limiting dilution titration in HCT116 cells. 
An MOI (multiplicity of infection) of 5 to 1 (5 transducing viral particles to 1 cell) was 
used for transducing cells using Polybrene (Sigma-Aldrich) at a final concentration of 
8 µg/ml to increase transduction efficiency. Twenty-four hours after transduction, 
puromycin selection was started and mutant TP53_silenced cells were immediately 
used for in vitro experiments, protein and RNA extraction. 
Similarly, to generate MET-5A-Tween cell line, we transduced cells with a lentivirus to 
express Tween and then sorted by FACS.  
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3.3. Cell treatment 
Nutlin-3 (Cayman Chemical) treatment was performed as follows: MCF10a cells plated 
24 hours earlier in 10 cm plates were exposed for 24 hours to Nutlin-3 at the final 
concentration of 10 µM in complete medium. 
 
3.4. Integrin detection 
Integrins were measured by FACS using αII (12F1, BD-Bioscience), Integrin α3 
(MAB1952Z, Chemicon Int.), Integrin α4 (9F10, BD-Bioscience), Integrin α5 (IIA1, 
BD-Bioscience), Integrin α9β1 (MAB2078Z, Chemicon Int.), Integrin αVβ3 
(MAB1976X, Chemicon Int.). To this end, cells were detached from culture dishes, 
pelleted and suspended in 10% FBS at a final concentration 6x10^6 cells/ml. 50 µl of 
cell suspension was stained on ice with 5 µl of antibody for 30 min. Cells were washed 
with ice-cold PBS and analyzed using the BD FACScan flow cytometer system. 
 
3.5. Mesothelial clearance assay 
To test the ability of OvCa cell lines to invade the peritoneum, we used the in vitro 
mesothelial clearance assay 354. To form spheroids, 100 ovarian cancer cells stained 
with DiI (red) were plated in one well of a 96-well U-bottom plate coated with poly-
HEMA (poly-2- hydroxyethyl methacrylate, Sigma-Aldrich). polyHEMA is a polymer 
that forms a hydrogel in water 355 and due to its uniformly nonionic nature, it effectively 
prevents matrix deposition when used to coat cell culture dishes and so allow the 
growth in suspension. At the same time, MET-5A-Tween cells were plated on a 6-well 
dish coated with 5 µg/ml fibronectin (Sigma-Aldrich) to resemble the mesothelium 
monolayer. After 16 hours, the spheroids were collected and plated on the MET-5A-
Tween monolayer. The plate was then transferred to the time-lapse microscope (Leica 
Time Lapse AF6000LX) interfaced with the Leica Application Suite (LAS) software, 
where we observed at least 20 spheroids for each treatment over a period of 8 hours, 
using bright-field and fluorescence filters at 200x magnification. Images were captured 
every 2 hours and analyzed using ImageJ software by measuring the area of each sphe-
roid at time 0 (t0) and the area of the hole in the MET-5A-Tween monolayer after 8 
hours (t8) 356. Normalized clearance area is defined as the ratio between t8 and t0 ac-
cording to 354. 
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3.6. 3D colony assay formation 
To test the ability of BC cell lines to invade extracellular matrix, we cultured them in 
Matrigel. Matrigel matrix (Geltrex® LDEV-Free Reduced Growth Factor Basement 
Membrane Matrix, Thermo Fisher Scientific) was thawed overnight in ice before use. 
The day after, 2000 cells were plated with 150 µl of Matrigel matrix in 4 well of a 
polyHEMA coated 96-plate. The plate has been incubated at 37°C for 30 min to allow 
the Matrigel matrix to gel, then 120 µl of complete medium were added. After 10 days 
cells were stained with 2 µg/ml calcein for 30 minutes at 37°C (Life Technologies) and 
cell morphology was observed using a confocal laser-scanning microscope (TSP2 
Leica) interfaced with a Leica DMIRE2 fluorescent. 
 
3.7. Western blotting (WB) 
To obtain protein extract, cells were incubated for 20 minutes on ice in NP40 buffer 
(0.5% NP40, 50 mM HEPES, 250 mM NaCl, 5 mM EDTA, 0.5 mM EGTA, 1 µM 
DTT) supplemented with Protease Inhibitors (Complete; Roche, Mannheim, Ger-
many) and Phosphatase Inhibitor Cocktail 1 and 2 (P2850 and P5726; Sigma-Aldrich). 
Cells were vortexed every 5 minutes and then clarified by centrifugation at maximum 
speed for 20 minutes at 4°C (NP40-soluble fraction). Cell pellets, obtained after clari-
fication, were suspended in SDS lysis buffer (4% SDS, 100 mM Tris-HCl pH 6.8, 20% 
glycerol) and boiled for 10 minutes at 95°C (NP40-insoluble fraction). The protein 
concentration of NP40-soluble fraction was quantified by Bradford assay using the 
Protein Assay Dye Reagent Concentrate (Bio-Rad, Hercules, CA, USA), whereas the 
concentration of the NP40-insoluble fraction was empirically derived from its corre-
sponding soluble fraction. 
For immunoblotting analysis, 40 µg of proteins were boiled in 5X sample buffer (Tris 
HCl 1M pH 6.8, SDS 10%, glycerol 80%, bromophenol blue 0.4%, β-mercaptoetha-
nol) for 10 minutes, separated using 4-20% SDS-PAGE Criterion TGX Stain-Free 
Precast Gels (Bio-Rad) and transferred to PVDF or nitrocellulose membranes (Bio-
Rad). Membranes were blocked with 5% non-fat dried milk in TBS-Tween20 (20 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 0,1% Tween 20) or in Odyssey Blocking buffer (Li-
cor) for 1 hour at room temperature and then incubated overnight at 4°C with the 
following antibodies: p53 (sc-126 Santa Cruz), E-cadherin (cat. no.36; BD-Bioscience), 
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H2AX (cat. no.2595; Cell Signaling, Danvers, MA, USA), Pax8 (10336-1-AP Protein 
Tech), vimentin (D21H3; Cell Signaling), vinculin (sc-73614; Santa Cruz). Incubation 
with the secondary antibodies anti-rabbit, anti-mouse or anti-goat linked with horse-
radish peroxidase (HRP) (GE Healthcare Lifesciences, Little Chalfont, UK) was per-
formed for 1 hour at room temperature at a dilution 1:3000-1:5000. According to sig-
nal intensity, secondary antibody detection was performed using either ECL Western 
Blotting Detection Reagents RPN 2106 (GE Healthcare) or Luminata Forte Western 
HRP Substrate (Merck Millipore, Darmstadt, Germany) and using Chemidoc MP Im-
ager (Bio-Rad). Band intensities were analyzed and quantified using Image Lab v5.2 
(Bio-rad). 
 
3.8. Nucleus/cytoplasmic separation 
Cells were collected using a scraper and suspended in ice-cold RSB buffer (10 mM 
Tris-Cl pH 7.4, 10 mM NaCl, 3 mM MgCl2) with 0,025% or 0,050% NP40 and pro-
teinase inhibitor (cOmplete Protease Inhibitor Tablets, Sigma) and centrifuged at 400g 
for 15 minutes at 4°C. The supernatant was centrifuged at maximum speed to remove 
debris, supernatant represents the cytoplasmic enriched fraction. The pellet, containing 
the intact nuclei, was washed with ice-cold RSB buffer with 0,025% or 0,050% NP40 
and spun for 15 minutes at 400g at 4°C to remove cellular debris. 
 
3.9. RNA extraction, cDNA synthesis and Quantitative 
Real-Time PCR (qRT-PCR) 
Total and nuclear RNA was extracted using Isol-RNA Lysis Reagent (5 Prime, Ham-
burg, Germany), whereas cytoplasmic RNA was isolated from the supernatant using 
TRIzol LS reagent (Life Technologies), according to protocol instructions. RNA ex-
traction was followed by cleanup with spin columns (RNeasy MinElute Cleanup Kit, 
Qiagen), DNase digestion (Turbo-DNase, Ambion, Thermo Fisher Scientific). RNA 
quality was tested by agarose gel electrophoresis after RNA exposure to 70°C for 5 
minutes. 1 µg of RNA was reverse transcribed in cDNA using AMV Reverse Tran-
scriptase (Promega) and random primers (Promega). qRT-PCR was performed in du-
plicate using iQ SYBR Green Mix (Bio-Rad) with the appropriate primers, as reported 
in Table 2. Primer sequences were designed using Primer 3 Plus 357 and purchased from 
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Sigma-Aldrich. qRT-PCR reaction was carried out either in 96-well optical reaction 
plates using Two-Color Real-Time PCR Detection System MyiQ2 (Biorad) or in 384-
well optical reaction plates using Applied Biosystems 7900HT Fast Real-Time PCR 
System (Thermo Fisher Scientific), according to manufacturer 's protocol. To calculate 
the relative abundance of RNA genes we used the 2−ΔΔCt formula and adopted 
GAPDH as housekeeping control gene. 
 
Primer name Primer 5 sequence (5’-3’) Primer 3 sequence (5’-3’) 
TP53 GCCGTCCCAGCAATGGATGATTT TCTGGCATTCTGGGAGCTTCATCT 
GAPDH GAGAGACCCTCACTGCTG GATGGTACATGACAAGGTGC 
PAX8 GCAACCATTCAACCTCCCTA CTGCTGCTGCTCTGTGAGTC 
CDH1 TGCCCAGAAAATGAAAAAGG GTGTATGTGGCAATGCGTTC 
H-VIMENTIN GAGAACTTTGCCGTTGAAGC GCTTCCTGTAGGTGGCAATC 
CDKN1A GGACCTGGAGACTCTCA CCTCTTGGAGAAGATCAG 
SLUG GGGGAGAAGCCTTTTTCTTG TCCTCATGTTTGTGCAGGAG 
BNC2_intr2 TGGGAACAGAATTGCCATAA CCACCCCCAGCACTATTTTA 
SCARNA2 GTGCAGGGTGAGTGTGAGTG GCAGGAGGAGAGCTTTTCATT 
BAIAP2-AS1 GGAAAGTTGAATGGCTGGAA TTTTCCGGAGAAGCCTACCT 
RP11-166D19.1 TGTTCCTTTCAGCTGGTCCT GCAGAGGAGGTGTCTTCAGG 
RP11-244M2.1 GAGCCTTATGTATGTGGTTGAAA TGCCCAGAGGAAAAATAGTGA 
AC034220.3 CTTTGAGGGGTCCATGTGAT CATGAAGTTGCAGTCAAGCTG 
LINC00704 TTTCAGAACCCTGCATTTCC ACAGGGGTGTGGAGTCAGAG 
MALAT1 CAATGAAGAGGCAATGTCCA AAACGAAACATTGGCACACA 
RP11-527N22.2 ACAAGGCGAGGACAAGAAGA CAGATTCTGCCCTTCGCTAC 
LINC01547 CACATCTGCCTCATTCCAGA TGCGTTTGGCAGACTCATAG 
RP11-47A8.5 ATTGGAAGAAGTCGGCAGAA GATGAGAGTGTTGGGGTTGG 
MIR100HG CGCGTGGATGATTTGAAGAT AGCATGCCCTAAAAATTTGC 
LINC00472 CAGGTACTCCACTGGGCATT CCACATGGCCCAACTAAGAG 
RP11-108P20.2 TGCTAGCAAGCCACATCTTG GAAAAGCCTCCTGACTGCAC 
RP11-362F19.1 TCCTTCTCCACCTCAACCAC GGGACACATGCTTCTAGTCTTG 
RP11-25I15.3 AACATGGCATGATTTCCACA AGAAATCACCCGCCTTCTG 
RMRP ACTCTGTTCCTCCCCTTTCC CTAGAGGGAGCTGACGGATG 
AC016710.1 AACAGGTCCTCACTGCCCTA CCATGTTGTTCCCTCCCATA 
LINC00621 CCAAGTCTGGTCAACCCAAT AGCAGCTGGATTGCAGTTTT 
AP001628.6 GAGGCTGAGGCAGGATCAC TATGACCTTGTCCCCTCTCG 
RP11-176D17.3 CCAGGTTTAAAGGTGGCTGT GGATACATAAAGCATCTACCCACA 
RP11-7F17.7 TACGGCCAAGACCATAGACC CTTCCCTCATGGGACAAAAA 
TERC AAGAGTTGGGCTCTGTCAGC AAGCGAACTGCATGTGTGAG 
CDK5 CTTGTGGAGTGGGTGGCTAT CCACTTGGTGTCCAGAACCT 
CDK14 GACCATTGAGGACCTGAGGA GGCTCTCAATCTGCATCTCC 
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CDK18 TGGAGCCATTACTTCAAGATCA TGGCCAGCTCTGTCTCATAC 
CDK19 ACTACAGCCACTACTACACGACCAT GTCTCAAACTTGGTTCGGAAGTC 
ACTA1 CTCACTGAGCGTGGCTACTCC CTTGATGTCGCGCACGATC 
ESR1 TGGGCTTACTGACCAACCTG CCTGATCATGGAGGGTCAAA 
ZEB1 CAGGCAGATGAAGCAGGATG GACCACTGGCTTCTGGTGTG 
ZEB2 GCGCTTGACATCACTGAAGG ACCTGCTCCTTGGGTTAGCA 
TWIST GGAGTCCGCAGTCTTACGAG TCTGGAGGACCTGGTAGAGG 
SOX9 GACCAGTACCCGCACTT TTCACCGACTTCCTCCG 
HAS2 GCCTCATCTGTGGAGATGGT ATGCACTGAACACACCCAAA 
Table 2: Primer sequences. 
 
3.10. Deep-sequencing Library preparation and sequenc-
ing 
1 µg of good quality RNA (R.I.N. > 7) nuclear RNA were sent to IGA Technologies 
(Udine) to perform the deep-sequencing analysis.  
For Cov318, ‘Ovation RNA-Seq System V2’ (NuGEN, San Carlos, CA) has been used 
for cDNA amplification following the manufacturer’s instructions. 10 ng of cDNA 
was fragmented using Bioraptor (Diagenode, Liége, Belgium) using 15’’ of “high-
mode” fragmentation for 6 cycles. Subsequently ‘Ovation Ultralow System V2 1-96’ 
has been used for library preparation following the manufacturer’s instructions. 
For MDA-MB-231, ‘TruSeq Stranded mRNA Sample Prep kit’ (Illumina, San Diego, 
CA) has been used for library preparation following the manufacturer’s instructions. 
The poly-A mRNA was fragmented 3 minutes at 94°C and every purification step has 
been performed by using 1X Agencourt AMPure XP beads. 
 
cDNA and final libraries were quantified by using the Qubit 2.0 Fluorometer (Invitro-
gen, Carlsbad, CA) and quality tested by Agilent 2100 Bioanalyzer High Sensitivity or 
DNA 1000 chip (Agilent technologies, Santa Clara, CA). Libraries were then processed 
with Illumina cBot for cluster generation on the flowcell, following the manufacturer’s 
instructions and sequenced on single-end mode at the multiplexing level requested on 
HiSeq2500 (Illumina, San Diego, CA). The CASAVA 1.8.2 version of the Illumina 
pipeline was used to processed raw data for both format conversion and de-multiplex-
ing. 
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3.11. Statistical Analysis 
Graphs presented in figures were obtained using GraphPad Prism v6.0d software (La 
Jolla, CA, USA) and statistical analyses were done using JMP v9.0.1 software (Carry, 
NC, USA). Data were examined using the two-tailed Student’s t-test assuming unequal 
variances or one-way ANOVA test when we compared more than two groups at once. 
Differences were considered significant at p < 0.05 and p <0.01 and labeled accord-
ingly (* or **, respectively).  
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4. Results 
4.1. Cell models characterization 
4.1.1. Ovarian cancer cell models 
To characterize HGSOC ability to metastatize in vitro, we first selected 8 commercial 
EOC cell lines (Table 3) that belong likely or possibly to HGSOC according to 
Domcke et al. 358. Domcke et al. classified commercial EOC cell lines based on: 
histological subtype of tumors from which EOC cell lines were derived according to 
original publication, number of mutations per million bases, copy number alteration 
prolife, and mutation in TP53, BRCA1 or BRCA2, ARID1, RB, PI3K, PTEN, ERBB2, 
KRAS, BRAF and CTNNB1 genes. 
 
Cell line 
name 
Similarity to 
HGSOC 358 
TP53 status 21 
Exon Codon Mutation de-scription Wt → mut codon 
Kuramochi Likely HGSOC 8 281 c.841G>T missense GAC → TAC 
Ovsaho Likely HGSOC 10 342 c.1024C>T missense CGA → Stop codon 
Cov362 Likely HGSOC 6 220 c.659A>G missense TAT → TGT 
Ovcar4 Likely HGSOC 5 130 c.388 C > G missense CTC → GTC 
Cov318 Likely HGSOC 6 195 c.583 A > T missense ATC → TTC 
Cov504 Possibly HGSOC 9 322 c.965_966 deletion frameshift CCA → Stop codon 
Ov90 Possibly HGSOC 9 215 c.643A>C missense AGT → CGT 
Tov112D Endometrioid 5 175 c.524G>A missense CGC → CAC 
Table 3: Classification and TP53 mutations in our HGSOC models. 
 
To confirm the presence of TP53 mutations and to confirm HGSOC orgin of the 8 
cell lines, we sequenced TP53 and evaluated p53 and Pax8 protein expression by WB. 
Pax8 is a transcription factor, which regulates organogenesis of Müllerian structures 
with a critical role in OvCa development 359. In all cell lines, we identified the expected 
TP53 mutation according to IARC TP53 database 21 (Table 3). The protein expression 
of p53 was absent in Ovsaho and Cov504, which carry a nonsense mutation; whereas, 
all the other cell lines expressed the mutant protein (Figure 7A). Pax8 protein 
expression was present in all cell lines except Ov90 (Figure 7C). 
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Once we confirmed the presence and expression of mutant TP53 and Pax8, we tested 
the 8 cell lines, for their ability to clear the mesothelium as described in 354 and in 
Materials and methods section of this Thesis (Mesothelial clearance assay). All 8 cells 
proved to be competent to clear mesothelium layer similarly to positive control 
(Tov112D), having all a median normalized clearance area (area of the hole in the 
MET-5A-Tween monolayer after 8 hours divided by area of tumor spheroid at time 
0) greater than 1; being Cov318, Cov362, Ovcar4 and Cov504 the most efficient ones 
(Figure 7B). 
Since Davidowitz and colleagues demonstrated that OvCa cells clearance capability is 
directly proportional to the expression of EMT proteins 360, we evaluated by WB 
and/or qRT-PCR the expression of E-cadherin (epithelial marker), Slug and Vimentin 
(mesenchymal markers) in our OvCa cell models (Figure 7D and E). E-cadherin is 
expressed in Ovsaho, Ovcar4, Cov504 and Ov90; whereas, Slug is highly expressed 
only in Cov504 and Vimentin is highly expressed in Cov362, Kuramochi and Cov504. 
In our cell models, there was not an evident correlation between EMT markers and 
intrinsic mesothelial clearance ability. 
Furthermore, since it has already demonstrated that OvCa spheroids clear the meso-
thelium using a α5-integrin-dependent activation of myosin, which on its turn induces 
a traction force that promotes mesothelial cells displacement 361, we investigated 
whether the difference that we observed in mesothelial clearance ability could be due 
to α5-integrin different expression. The results we obtained are not consistent with 
previous reports 361, indeed in Cov318 (the most competent to clear the monolayer), 
only a small percentage of cells express α5 (Figure 7F). Therefore, we profiled the 
expression of other fibronectin-binding integrins in Cov318 cells, and we found that 
the most expressed integrin is the α3 chain (Figure 7G). 
Finally, we decided to use Cov318 and Cov362 for further experiments, because they 
have good clearance ability, harbor a missense mutation in p53, form stable and com-
pact spheroids and have EMT traits. 
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Figure 7: HGSOC cell models characterization. (A) Western Blotting detection of p53 in NP40-insoluble 
protein extracts from eight OvCa cell lines. Ponceau staining was used as loading control. (B) Quantification of meso-
thelial clearance ability of eight OvCa cell lines. A total of 20 spheroid were analyzed per cell models. Data are shown 
as the mean ± standard deviation. (C) Western Blotting detection and qRT-PCR analysis of PAX8. Data are shown 
as the mean ± standard deviation of two technical replicates. (D) Western Blotting detection of E-cadherin and Vi-
mentin. Ponceau staining was used as loading control. (E) qRT-PCR analysis of E-CADHERIN, SLUG and VI-
MENTIN. Data are shown as the mean ± standard deviation of two technical replicates. (F) Expression of a5-integ-
rin in three OvCa cell models. (G) A panel of expression of six different integrin in Cov318. 
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4.1.2. Breast cancer cell models 
As for OvCa, to characterize BC invasiveness ability in vitro, we selected 8 commercial 
BC cell lines which all carry TP53 mutations (reported in Table 4). Neve and colleagues 
362 catalogated BC cell lines for their genomic and molecular proprieties and subdivided 
into luminal or basal B BC (Table 4).  
 
Cell line 
name 
Classification 
362 
TP53 status 21 
Exon Codon Mutation de-
scription 
Wt → mut codon 
MDA-MB-415 Luminal 7 236 c.707A>G missense TAC → TGC 
BT474 Luminal 8 285 c.835G>A missense GAG → AAG 
T47D Luminal 6 194 c.580C>T missense CTT → TTT 
SKBR3 Luminal 5 175 c.524G>A missense CGC → CAC 
MDA-MB-231 Basal B 8 280 c.839G>A missense AGA → AAA 
SUM149PT Basal B 7 237 c.711G>A missense ATG → ATA 
Hs578T Basal B 5 157 c.469G>T missense GTC → TTC 
BT549 Basal B 7 249 c.747G>C missense AGG → AGC 
Table 4: Classification and TP53 mutations in our BC models. 
 
To confirm this classification in our own cell models, we evaluated the expression 
those cytokeratins (CK) that differentiate BC into luminal and basal subtypes accord-
ing to 362. As expected by literature, we confirmed the enrichment of luminal CKs 
(CK18 and CK19) in MDA-MB-415, BT474, T47D and SKBR3 cell models and basal 
CKs (CK5 and CK14) in MDA-MB-231, SUM149PT, Hs578T and BT549 (Figure 8). 
Moreover, since basal BC is the most aggressive BC subtype and it is associated with 
mesenchymal features, we evaluated the expression of several mesenchymal (ACTA1, 
HAS2, SOX9, SLUG, TWIST, VIMENTIN, ZEB1, ZEB2) and epithelial (CDH1) 
markers in these cell models. All the mesenchymal markers were expressed only in the 
basal cell models, except for ACTA1 and SOX9 that were also present in the luminal 
models. At the same time, we evaluated estrogen receptor (ESR1), which was overex-
pressed in the luminal subtypes (Figure 8). TP53 mutations are more frequent in basal 
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BC and MDA-MB-231 was previously used to investigate mut_p53 effect; therefore, 
we decided use as well this cell line. 
 
 
Figure 8: BC cell models characterization. qRT-PCR analysis of several mesenchymal and epithelial genes 
(VIMENTIN, ACTA1, CDH1, ZEB1, ZEB2, TWIST, SLUG, SOX9, HAS2), basal cytokeratins (CK5. 
CK14), luminal cytokeratins (CK18, CK19) and estrogen receptor1 (ESR1). Data are shown as the mean ± stand-
ard deviation of two technical replicates. 
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4.2. Evaluation of mut_p53 in in vitro assays 
4.2.1. The role of mut_p53 in HGSOC cells mesothelial 
clearance 
To investigate whether mut_p53 drives an invasive advantage in OvCa cells, we engi-
neered Cov318 and Cov362 cell lines to express two inducible shRNAs that target 
TP53. After 4 days of induction with IPTG (Figure 9A and C), we used these cells to 
perform the mesothelial clearance assay and observed that, in both cell lines, TP53 
silencing caused a significant reduction of their clearance capability compared to con-
trol cells (Figure 9B and D). 
 
 
Figure 9: Mesothelial clearance assay of Cov318 and Cov362 TP53_silenced. Western Blotting detec-
tion of p53 protein reduction after 4 days of cell induction with IPTG in (A) Cov318 and in (C) Cov362. (B) 
Cov318 and (D) Cov362 quantification of mesothelial clearance assay. The normalized clearance area is obtained by 
dividing the spheroids area at t=0 for the hole in the mesothelial at 8 hours. These results are the mean of 3 experi-
ments. 
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4.2.2. The role of mut_p53 in BC 3D colony formation 
To investigate whether mut_p53 confers an invasive advantage to BC cells, we engi-
neered MDA-MB-231 cell line to express two constitutive shRNAs that target TP53 
(Figure 10A) and tested them in 3D colony assay formation. Notably, silenced cells 
acquired a round shaped morphology and adhered less to cell dishes (data not shown). 
Four-five days after viral transduction, silenced cells stopped to proliferate (Figure 
10B), which is consistent with the oncogenic function of mut_p53 (refer to paragraph 
Clinical implications); however, 9-10 days later, TP53_silenced cells would start grow-
ing again. (Figure 10B). Therefore, to avoid the effect of TP53 silencing on cell prolif-
eration, we decided to test 3D colony formation after 10 days from viral transduction. 
By these means, we observed that whereas control cells invaded the extracellular ma-
trix and formed star-shaped colonies (Circularity count of Figure 10C), TP53_silenced 
cells despite being able to grow similarly to control cells (Area count of Figure 10C) 
did not invade the extracellular matrix and formed round-shaped colonies (Circularity 
count of Figure 10C). 
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Figure 10: 3D colony assay of MDA-MB-231 TP53_silenced. (A) Western Blotting detection of p53 pro-
tein reduction. (B) Population doubling of MDA-MB-231. (C) Quantification of 3D colony circularity and represen-
tation of typical images obtained with fluorescence confocal microscopy after stained with calcein. Images were acquired 10 
days after the plating. Circularity were evaluated using ImageJ. ImageJ gives a value 1 to circular colonies, whilst the 
more spreaded colonies are, the more the values is close to 0. A total of 10 fields were analyzed per conditions. These re-
sults are the mean of 2 experiments. Area of the colony 10 days after the plating, measured with ImageJ. 
 
4.3. Profile the expression of lncRNAs using RNA deep-
sequencing analysis 
To evaluate whether mut_p53 regulates gene expression of lncRNAs in HGSOC and 
in BC, we performed a RNA deep-sequencing analysis of Cov318 and MDA-MB-231 
TP53_silenced cells. 
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4.3.1. Sample preparation 
Because Marchese et al. described that lincRNAs are primarily enriched in the nucleus, 
where they regulate gene expression 363, we decided to sequence only RNA nuclear 
fraction. We performed a separation of nuclear and cytoplasmic fractions using the 
protocol described in Materials and methods section of this Thesis (Nucleus/cytoplas-
mic separation). To verify the quality of the obtained subcellular fractionation, we 
measured vinculin and histone 2AX (H2AX) protein expression, which resulted en-
riched in the cytosolic and nuclear fraction, respectively (Figure 11A and C). Similarly, 
only for Cov318, we evaluated the nuclear enrichment of one of the introns of BNC2 
protein-coding gene by qRT-PCR (Figure 11B), this analysis was not performed for 
MDA-MB-231 cells, because they do not express BNC2. To identify lncRNA genes 
that changed after TP53 silencing, we performed Next Generation Sequencing (NGS) 
of RNA nuclear fraction in Cov318 and MDA-MB-231 silenced for TP53 with two 
different shRNAs and after 11 days from viral transduction (Figure 11A and C). For 
each cell line, we analyzed two independent biological replicates. 
 
 
Figure 11: Evaluation of the correct nucleus and cytoplasmic fraction separation. Western Blotting 
detection of vinculin and H2AX in (A) Cov318 and in (C) MDA-MB-231. (B) qRT-PCR analysis of BNC2 
intron enrichment in Cov318 nuclear fraction. 
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4.3.2. Deep-sequencing output 
On average, we obtained 40 millions sequences (125nt long) per sample in Cov318 
experiment, and 30 millions sequences (150nt long) per samples in MDA-MB-231 ex-
periment. To check run quality, we used FastQC algorithm on FastQ outputs. In gen-
eral, MDA-MB-231 sequences had a much better quality than Cov318 samples (Figure 
12). 
 
 
Figure 12: FastQ quality. An example of output of FastQ quality evaluated with FastQC software of (A) Cov318 
and (B) MDA-MB-231. 
 
To analyze data obtained from NGS runs, we used two different strategies: the first 
analyzed reads based on transcripts (each gene has multiple transcripts that are indi-
vidually counted), the second analyzed reads according to gene locus (all reads aligned 
to a gene locus are summed). 
A B
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4.3.3. Transcript differentially expressed 
In this analysis, we used a standard pipeline of RNA deep-sequencing analysis as de-
scribed in Figure 13. We set a minimum base quality score of 30 and we removed 
adapter sequences using Trimmomatic 364. We mapped reads longer than 50nt allowing 
2 mismatches to the reference genome (Gencode V25) using the software Salmon 365 . 
To perform differential expression analysis, we used edgeR package of R 366. By com-
paring TP53 silenced samples to controls in Cov318, we obtained 721 transcripts dif-
ferentially expressed (FDR ≤ 0.05), among these 361 are annotated as protein-coding 
transcripts in GencodeV25 and 360 are annotated as ncRNAs (in particular 105 are 
processed transcripts, 91 retained introns, 48 nonsense-mediated decays and 33 are 
lincRNAs). Among the 721 transcripts, 292 are downregulated instead 429 are upreg-
ulated when mut_p53 is silenced. For MDA-MB-231, we obtained 69 transcripts dif-
ferentially expressed (FDR ≤ 0.05), among these 56 are annotated as protein-coding 
transcripts in GencodeV25 and 13 are annotated as ncRNAs (in particular 4 retained 
introns, 4 are processed transcripts, 3 nonsense-mediated decays and only 1 are lin-
cRNA). Among the 69 transcripts, 3 are downregulated instead 63 are upregulated 
when mut_p53 is silenced. 
 
 
Figure 13: Deep-sequencing analysis pipeline to identify transcripts differentially expressed. 
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To validate Cov318 and MDA-MB-231 analysis, we selected non_coding transcripts 
with a FDR less than 0.05 and with an absolute logFC value higher than 1. 
We designed qRT-PCR primers for each candidate ncRNA transcript, and tested their 
gene expression levels on the cytoplasmic and nuclear RNA fraction of Cov318 and 
MDA-MB_231 cell lines. Unfortunately, we found that all these transcripts except one 
(TERC) were not detectable, so we decided to use a different strategy. 
 
4.3.4. Gene locus differentially expressed analysis 
While we analyzed the data based on transcripts, we realized that because we se-
quenced samples derived from the RNA nuclear fraction, many reads matched to the 
intronic part of genes (both coding and non-coding), which is certainly expected, be-
cause typically introns are retained in the nucleus and soon degraded (Figure 11B). At 
the same time, intronic reads are still a read-out of gene transcription and regulation; 
but more importantly, regulatory elements of gene expression (promoters and enhanc-
ers) located within or close to gene transcripts generate reads that do not participate 
to transcript synthesis but are a read-out of the regulatory element activity 367. There-
fore, we reasoned that because we sequenced nuclear RNA), the first transcript-centric 
approach lost several layers of information; whereas, a gene-centric approach could be 
more informative. In the gene-centric approach, we considered as gene unit not only 
the exonic part but also the intronic and the regulatory regions of the gene unit itself. 
To this aim, we set up a custom pipeline (Figure 14). To generate the library of human 
gene units, we started from Homo sapiens grch37 reference genome, and we merged the 
genomic intervals of all transcripts annotated to the same gene thus generating the 
most comprehensive interval for each gene unit. We mapped reads to the gene units 
library using Hisat2 software 368, assembled the genes and estimated their abundances 
utilizing the software Featurecounts 369. To perform differential expression analysis, 
we used DESeq2 package370 in R. 
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Figure 14: Deep-sequencing analysis pipeline to identify genes differentially expressed. 
 
By comparing TP53 silenced samples to controls in Cov318, we obtained 806 genes 
differentially expressed (adj_pvalue ≤ 0.05), among these 680 are annotated as protein-
coding genes in GencodeV24 and 126 are annotated as ncRNAs (in particular 62 are 
lincRNAs and 23 antisense) (Figure 15A). Among the 806 genes, 341 are downregu-
lated whereas 465 are upregulated when TP53 is silenced. For MDA-MB-231, we 
found 1820 genes differentially expressed (adj_pvalue ≤ 0.05): 1616 are annotated as 
protein-coding genes and 204 as ncRNAs (among these 99 as lincRNAs and 38 as 
antisense) (Figure 15B). Among 1820, 725 are downregulated and 1095 are upregulated 
when TP53 is silenced. 
 
Figure 15: Gene types of genes differentially expressed in (A) Cov318 and in (B) M231. 
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To validate Cov318 and MDA-MB-231 analysis, for each cell line, we selected the 10 
lncRNA transcripts with the lowest adj_pvalue and 2 significant transcripts that 
changed concordantly in both cell lines. Only gene units with a normalized baseMean 
read count greater than 20 were included (Table 5 and Table 6). 
 
Gene Gene_id GeneType Log2FC padj 
qRT-PCR 
Ct nuclear 
fraction 
RP11-108P20.2 ENSG00000267501 lincRNA 1,365474 0,0000006 28,9 
RP11-362F19.1 ENSG00000248810 lincRNA -0,770444 0,0000055 20,6 
RP11-25I15.3 ENSG00000257114 lincRNA 0,826190 0,0000859 22,3 
RMRP ENSG00000269900 lincRNA 0,819893 0,0003735 18,8 
AC016710.1 ENSG00000229131 lincRNA 0,894757 0,0013520 26,6 
LINC00621 ENSG00000262619 lincRNA 0,540043 0,0027134 22,3 
AP001628.6 ENSG00000225218 lincRNA 0,718073 0,0047863 29,7 
TERC ENSG00000270141 lincRNA 0,971149 0,0050568 27,7 
RP11-176D17.3 ENSG00000228470 sense_overlapping 0,732544 0,0069626 24,5 
RP11-7F17.7 ENSG00000258602 lincRNA 0,885050 0,0077469 24,7 
SCARNA2 ENSG00000270066 lincRNA 0,949619 0,0007345 26,1 
BAIAP2-AS1 ENSG00000226137 lincRNA 0,818278 0,0253519 25,4 
Table 5: Genes chose to be validated in Cov318. 
 
Gene Gene_id GeneType Log2FC padj 
qRT-PCR 
Ct nuclear 
fraction 
RP11-166D19.1 ENSG00000255248 sense_overlapping -0,826360 0,0000044 20,3 
RP11-244M2.1 ENSG00000267374 lincRNA -0,796658 0,0000055 23,1 
AC034220.3 ENSG00000233006 processed_transcript 0,762843 0,0000454 24,5 
LINC00704 ENSG00000231298 lincRNA -0,889951 0,0000459 20,9 
MALAT1 ENSG00000251562 lincRNA 0,920520 0,0005078 15,1 
RP11-527N22.2 ENSG00000253746 lincRNA -1,025881 0,0006195 23,6 
LINC01547 ENSG00000183250 lincRNA 0,915840 0,0018320 26,2 
RP11-47A8.5 ENSG00000272933 lincRNA 1,198957 0,0029381 29,7 
MIR100HG ENSG00000224184 lincRNA -0,863958 0,0040484 18,7 
LINC00472 ENSG00000233237 lincRNA 0,535488 0,0072904 22,6 
SCARNA2 ENSG00000270066 lincRNA 0,566727 0,0405347 26,7 
BAIAP2-AS1 ENSG00000226137 lincRNA 0,739713 0,0118158 27,1 
Table 6: Genes chose to be validated in MDA-MB-231. 
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4.3.5. Deep-sequencing validation in mut_p53 cell models 
To validate candidate lncRNAs, we first tested their expression through qRT-PCR in 
the cytoplasmic and nuclear fraction of Cov318 and MDA-MB_231 parental cell lines. 
To distinguish expressed from not expressed lncRNAs, based on our experience, we 
set an arbitrary threshold of gene expression of 28 threshold cycles (Ct) in the RNA 
nuclear fraction that was satisfied by 8 out 10 lncRNAs in Cov318 and by 9 out of 10 
in MDA-MB-231 (Table 5 and Table 6). Moreover, we confirmed the enrichment of 
lncRNA in the nuclear respect to cytoplasmic fraction of Cov318 and MDA-MB_231 
parental cell lines (Figure 16A, B and C). 
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Figure 16: Expression of selected genes in cytoplasmic and nuclear fraction. qRT-PCR analysis of 
10 different candidate genes specific for (A) Cov318, (B) MDA-MB-231 and (C) in common among these two cell 
lines. Gene expressions are evaluated in nuclear and cytoplasmic fraction. 
 
Next, we investigated gene expression of candidate lncRNAs in TP53 silenced cells. In 
Cov318, we found that only two genes changed consistently between NGS and qRT-
A
B
c
RP11-166D19.1
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
50
100
150
200
250
RP11-244M2.1
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
10
20
30
40
AC034220.3
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
5
10
15
LINC00704
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
50
100
150
MALAT1
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
2000
4000
6000
8000
RP11-527N22.2
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
5
10
15
20
LINC01547
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
1
2
3
4
MIR100HG
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
200
400
600
800
LINC00472
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
10
20
30
40
50
RP11-362F19.1
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
0
50
100
150
200
RP11-25I15.3
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
0
20
40
60
RMRP
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
0
200
400
600
800
AC016710.1
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
0
1
2
3
LINC00621
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
0
20
40
60
TERC
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
0.0
0.5
1.0
1.5
RP11-176D17.3
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
0
5
10
15
RP11-7F17.7
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
0
5
10
15
SCARNA2
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
1
2
3
4
BAIAP2-AS1
Fo
ld
Ch
an
ge
re
la
tiv
e
to
G
A
PD
H
Co
v3
18
cy
to
Co
v3
18
nu
cle
us
MM
23
1 c
yto
MM
23
1 n
uc
leu
s
0
2
4
6
8
 
 
62 
PCR data (Figure 17A); in MDA-MB-231, we confirmed 8 out 9 lncRNAs BC-specific 
candidates (Figure 17B). 
Based on the poorer quality of Cov318 runs and poorer confirmation on qRT-PCR 
tests, we decided to focus only on MDA-MB-231. 
 
 
Figure 17: Validation of candidate genes. Gene expression are evaluated in the nuclear fraction of (A) Cov318 
and (B) MDA-MB-231 TP53_silenced.  
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4.3.6. Deep-sequencing validation in wt_p53 cell models 
TP53 missense mutants can retain part of wt_p53 transcription activity, which means 
that activation of wt_p53 and mut_p53 can have equal effect on common targets 371. 
To exclude that our candidate BC-specific lncRNAs were common targets of wt_p53 
and mut_p53, we evaluated their expression levels in a wt_p53 BC cell line (MCF10a) 
after exposure to Nutlin-3, a compound that inhibits Mdm2-p53 interaction thus pre-
venting p53 degradation. Nutlin-3 treatment increased expression levels of p53 and 
CDKN1A, a direct target of wt_p53 (Figure 18A). In this same cell model, we discov-
ered that 1 out of 9 lncRNAs was not expressed, that 1 candidate lncRNA was equally 
regulated by wt_p53 and mut_p53 and 3 lncRNAs were not regulated by wt_p53; 
whereas the remaining 3 lncRNAs were regulated oppositely by wt_p53 and mut_p53 
(Figure 18B). 
 
 
Figure 18: Expression of BC candidate genes in wt_p53 BC cell line. (A) qRT-PCR analysis of 
CDKN1A overexpression (left) and Western Blotting detection of p53 accumulation (right) after treatment with Nut-
lin-3 for 24 hours in MCF10a. (B) qRT-PCR analysis of candidate genes regulated by mut_p53. 
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5. Discussion 
Several common features characterize OvCa and BC, among these there are the high 
rate of mutations in TP53 and form tumor metastasis. Since several studies have 
demonstrated that mut_p53 GOF promotes tumor metastasis, but the molecular 
mechanisms are not fully characterized, we investigate whether lncRNAs participate 
in mut_p53 GOF. Indeed, some lncRNAs participate in wt_p53 pathway, but little is 
known about the role of lncRNAs on mut_p53 GOF. 
 
In particular, OvCa metastasizes the peritoneum after tumor cell clusters survived in 
the ascetic fluid and adhered and invaded the peritoneum. To study the ability of 
TP53_silenced cells to invade the mesothelium, we performed the in vitro mesothelial 
clearance assay 354, that resembles the interaction occurring in vivo between OvCa cell 
spheroids and peritoneum mesothelial cells. We observed that mut_p53 increases the 
ability of Cov318 and Cov362 OvCa cell lines to invade and spread the peritoneum, in 
agreement with Iwanicki et al. 372. Using this assay, Davidowitz and colleagues demon-
strated that OvCa cell use an integrin-dependent activation of myosin which induces 
a traction force to promote mesothelial displacement and integrin α5β1 (a fibronectin 
receptor) is the most important marker in this process 361. Nevertheless, we found that 
Cov318 clearance ability is not integrin α5 dependent, since Cov318 does not express 
it. At the same time, they found that mesenchymal genes expression (e.g. vimentin) 
correlates with mesothelial clearance ability; whereas, epithelial genes expression (e.g. 
E-cadherin, claudin7 and HER3) inversely correlates with clearance ability 360. How-
ever, in our models, we did not find apparent correlation with cells intrinsic mesothelial 
clearance ability and the expression of EMT genes. 
 
Likewise, we observed that mut_p53 increased MDA-MB-231 ability to invade extra-
cellular matrix when plated in a 3D Matrigel culture. We noticed that 4-5 days after 
transduction, TP53_silenced cells stopped to grow. To avoid this bias, we waited 9-10 
days after viral transduction, when cells started growing again, before evaluating the 
effect of mut_p53 silencing on invasion. Indeed, in the 3D Matrigel colony formation 
we observed that cell colonies silenced or not for mut_p53 are similar for dimension, 
but differ for the shape: control colonies were star-shaped, whereas TP53_silenced 
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cells colonies were round-shaped. Round-shape colonies have a typical epithelial mor-
phology and correlate to a less invasive phenotype, whereas the star-shaped colonies 
are more protrusive and acquired mesenchymal characteristics that indicate a more 
invasive phenotype. 
 
To investigate whether lncRNAs are involved in mut_p53 GOF, we sequenced the 
nuclear RNA fraction of Cov318 and MDA_MB_231 after TP53_silencing. First, we 
performed a standard pipeline of RNA deep-sequencing analysis to identify the 
lncRNA transcripts differentially expressed, but none of the selected transcripts were 
detectable at qRT-PCR. This can be explained because lncRNA are typically expressed 
at a very low level and often several transcripts are present for the same gene. Indeed, 
in this first analysis, significant transcripts were among those less expressed. For this 
reason, we choose to consider not the transcripts, but the genetic locus that encodes 
for a lncRNA and we set up a custom pipeline. When we performed this new analysis, 
we obtained genes detectable at qRT-PCR and we choose to validate the first 10 more 
differentially expressed and 2 in common between HGSOC and BC cell models. 
For Cov318, we were able to confirm through qRT-PCR only 2 lncRNAs obtained by 
NGS; whereas, in MDA-MB-231, we validated all the BC specific lncRNAs tested. We 
supposed this difference among Cov318 and MDA-MB-231 could be due to lower 
quality of Cov318 RNA sequenced or maybe some problems occurred during NGS 
run, as demonstrated by the FastQC output report. For these reasons, we focused our 
attention to MDA-MB-231, but we also plan to further investigate also two lncRNAs 
(RP11-362F19.1 and RP11-25I15.3) differentially expressed in Cov318 TP53_silenced.  
Using a wt_p53 BC cell model (MCF10a) treated with Nutlin-3 (an inhibitor of Mdm2) 
to overexpress wt_p53, we evaluated the BC-specific lncRNAs to excluded lncRNAs 
that are regulated both by wt_p53 and mut_p53. We found that 1 out of 9 lncRNAs 
was not expressed (RP11-527N22.2), indicating its expression was cell model specific; 
1 lncRNA was regulated both by wt_p53 and mut_p53 (RP11-166D19.1), 3 lncRNAs 
were not regulated by wt_p53 (MALAT1, LINC01547 and MIR100HG) and 3 
lncRNAs were regulated oppositely by wt_p53 and mut_p53 (RP11-244M2.1, 
AC034220.3 and LINC00704). 
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Interestingly, LINC00704 expression predicts BC recurrence 373. Our data are in agree-
ment with this study, since LINC00704 is significantly downregulated in TP53_si-
lenced BC cell line, indicating a possible oncogenic role.  
MIR100HG is a polycistronic miRNA host gene of miR-100, let-7a-2 and miR-125b-
1. MIR100HG-derived miRNAs and MIR99AHG-derived miRNAs, participate in the 
pathogenesis of acute megakaryoblastic leukemia 374 and levels of MIR100HG are as-
sociated with a poor prognosis in cervical cancer 375, whereas its expression is reduced 
in BC, due to its hypermethylation 376. Moreover, MIR100HG confers cetuximab re-
sistance in colorectal cancer and in head and neck squamous cell cancer cell lines 377. 
MALAT1 is one of the first lncRNAs studied, it is involved in several cellular pro-
cesses (such as alternative splicing, nuclear organization, epigenetic modulation of gene 
expression) and it is related to several diseases. In cancer, it has been associated with 
an aggressive phenotype, in terms of cell proliferation and metastasis. It is localized to 
nuclear speckles, where regulated splicing. A study of Pruszko and et. demonstrates 
that in BC mut_p53 and the protein ID4 directly or indirectly delocalize MALAT1 
from nuclear speckles promoting its association with chromatin and allowing the for-
mation of a complex with the splicing factor SRSF1. This enables MALAT1 to control 
the expression of different isoforms of pre-mRNA 378. These observations are in dis-
accord with our data, since we observed an increase of MALAT1 expression when 
TP53 is silenced. 
Finally, our future plan is to investigate the impact of candidate lncRNAs on MDA-
MB-231 ability to invade and proliferate. Our strategy will be to use CRISPR-Cas9 tool 
to change lncRNAs expression. Specifically, we will use a nuclease dead Cas9 (dCas9) 
molecule that cannot cleave target DNA but retains the ability to bind to target DNA 
based on the gRNA targeting sequence. dCas9 is tagged with transcriptional repressors 
(e.g. KRAB) or activators (e.g. VP64) and when dCas9 bind the promoter of the target 
lncRNA, it can repress or activate its transcription. 
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